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ABSTRACT
The eponymous progressive palmar fibromatosis described by Guillaume Dupuytren in
1831 is a common and debilitating disease with limited treatment options and high rates
of recurrence after intervention. Dupuytren’s disease has been generally accepted as
predominantly affecting Northern European individuals; Dupuytren’s disease is
sometimes referred to as “Vikings Disease” as an attribution to this ethnic origin. Its
familial occurrence in all communities is suggestive of Mendelian inheritance as an
autosomal dominant disease with incomplete penetrance. The genetic and molecular basis
of Dupuytren’s disease (DD) has been the focus of many studies, with increasingly
sophisticated approaches since the sequencing of the human genome in 2003. However,
whilst the pathology of the progressive fibrosis is well understood, the etiology and
molecular triggers of the disease remain unknown.
This study has investigated the genetic basis of Dupuytren’s disease in families and the
population of Western Australia. The study involved a tripartite investigation in patients
from three different cohorts. The DNA of four DD affected people within a fourgeneration family with autosomal dominant inheritance of DD was submitted for whole
exome sequencing (WES) which initially identified 43 candidate genes with nonsynonymous heterozygous rare variants. Two candidate genes, EXOG and GORASP1,
were in regions of positive linkage whilst the remainder were not excluded by linkage
analysis. Sanger sequencing was focused on three candidate genes, EXOG, GORASP1 and
COL6A5, but no variant segregated with Dupuytren’s disease in additional family
members. No likely disease-causing variant was identified in all family members positive
for the disease phenotype.

A second cohort consisted of the Busselton study population, a study initiated in the 1960s
and following the health outcomes of nearly 5000 people in Busselton WA. Using a survey
48 unrelated individuals were identified as having had surgery for DD, whilst 409 people
had evidence of early DD. DNA from the participants of the Busselton study was screened
for SNPs using a GWAS chip approach and the data analysed to identify SNPs associated
7

with DD. This study lacked sufficient power to identify statistically significant SNPs
associated with the disease. A shortlist of variants was identified using an arbritrary pvalue cut-off. However, none of these SNPs were associated with genes in either the
familial study or previous research. For the final genetic study DNA from another set of
individuals with severe DD were subject to WES. The aim was to identify rare mutations
in genes that may be associated with DD and that would promote the more aggressive
phenotype in these individuals. Whilst no mutations in identical genes as previous studies
were identified there was overlap in gene families and networks that suggests pathways
that may be important in DD. Finally, fibroblasts isolated from some Dupuytren patients
and control fibroblasts from the wrist were characterized using a modified ‘scar-in-a-jar’
protocol to investigate their collagen production. Interestingly, this model did not identify
any differences between disease fibroblasts and control fibroblasts from the same patients.
This may suggest that profibrotic signals in Dupuytren disease are external to the
fibroblasts rather than autonomous. In addition it strongly suggests a need to develop more
complex models to reproduce the disease state in vitro for further studies to understand
the molecular basis of Dupuytren’s disease and
The complexity of the known genetic susceptibility together with environmental factors,
as well as the likely importance of non-coding and epigenetic factors continues to make
identification of the genetic changes underpinning Dupuytren’s disease difficult. In
addition limited in vitro and animal models for Dupuytren’s disease will continue to
hamper therapeutic development and understanding. However, the studies here suggest
common pathways may be implicated from the familial and population study approaches.
Further work to identify the functional changes that underpin DD will be critical to the
development of more effective treatment and prevention of the disease.
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CHAPTER 1
1.1 An overview of Dupuytren’s disease
Dupuytren’s disease is the most common heritable disorder of connective tissue (Hu et
al., 2005). Since his lectures to the staff at Hotel Dieu in Paris in 1831 (Dupuytren, 1834)
the name of Baron Dupuytren has received universal acceptance to describe this
progressive palmar fibromatosis, with or without contractures. Although he was unable to
identify the true pathophysiology or aetiology of this condition, attributing its
occupational cause to prolonged flexion of the digits in a coach-driver, Guillaume
Dupuytren (Fig.1.1) has been credited with the
earliest description of his eponymous disease.
Dupuytren’s disease is characteristically a lateonset fibromatosis affecting subcutaneous tissue of
the palms and fingers (Fig. 1.2). It is relatively rare
before the age of forty-five, with the mean age of
onset in males of all races at fifty years (+/- five
years) and fifty five years (+/- five years) in
females (Pearce, 1991).

Figure 1.1 Guillaume Dupuytren

In the pathogenesis of Dupuytren’s disease,

Progressive palmar fibromatosis was first

subcutaneous fat is progressively replaced by

described in 1831 by Baron Dupuytren

relatively avascular fibrous tissue, which develops
as nodules in the palm and extends distally into the

digits as thickened cords. Tender palmar nodules and progressive shortening of cords
across metacarpo-phalangeal and proximal interphalangeal joints, together with
subsequent changes in other structures including collateral ligaments, cause functional
disability (Fig. 1.2).
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Figure 1 2 Dupuytrens disease (DD (Palmar fibromatosis))
DD is shown here affecting the palm in a 45 year old male with fibrous nodules in the
palm extending as cords across the metacarpophalangeal and proximal interphalangeal
joints causing flexion contractures
Being a progressive condition that often presents in middle age with pain or digital
contractures, Dupuytren’s disease is a common cause of disability interfering with manual
dexterity in employment. In the majority of cases fibromatosis initially affects the palm
and little finger, spreading in time across the palm radially, involving sequentially the ring,
middle and index fingers. Less commonly there is a palpable band in the first web and
isolated contracture across the metacarpo-phalangeal (MCP) joint of the thumb. A further
unexplained occurrence is an isolated mid-palm cord extending into the middle finger with
early contracture at the MCP joint, a finding statistically associated with diabetes mellitus
(Ardic et al., 2003; Chammas et al., 1995; Eadington et al., 1989; Eadington et al., 1991;
Early, 1962; Herzog, 1951). Both trigger finger and Dupuytren’s disease are common in
the middle and ring fingers of the diabetic, sometimes referred to as the DDT syndrome
(Burgess & Watson, 1987; McFarlane, 1991; Parker, 1979).

Untreated digital contractures, particularly affecting both hands, can be very disabling as
they progress in association with other co-morbidities of ageing. While collagenase
injection into fibrous bands of Dupuytren’s tissue has met with limited success when used
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in early stages of the disease, surgical intervention in established cases is currently the
preferred treatment, with the best chance of functional recovery.

The clinical indications for medical or surgical intervention are related to disabling palmar
nodules, which can be painful and often interfere with everyday activities of life, or fibrous
cords extending across the small joints of the hand causing digital contractures with
limited extension of the metacarpo-phalangeal or proximal interphalangeal joints.
In summary, Dupuytren’s disease is a late onset progressive fibromatosis, predominantly
affecting males and with a disabling effect on the function of the hands. Whilst the clinical
manifestations of disease progression are easily recognized and well understood, the
molecular basis is not as clear.
1.2 Current clinical management of Dupuytren’s disease
1.2.1 Prevention
The aetiology of Dupuytren’s disease is not well understood, particularly in relation to the
part played by lifestyle and environmental factors. It is therefore not possible at this stage
to advise preventive measures beyond notifying those identified as being at risk (through
familial background) of the potentially harmful effects of smoking and alcohol. The
possible application of knowledge gained from an understanding of the genetic basis for
this disease to its prevention should be worth consideration. While epidemiological studies
provide often biased and conflicting evidence in relation to occupation as a causative
factor in Dupuytren’s disease there is no sound basis for considering employment in terms
of prevention (Mikkelsen, 1978).
1.3 Surgery to treat Dupuytren’s disease
Since the identification of Dupuytren’s disease as a progressive, debilitating condition,
surgery has been the primary treatment option. The majority of Dupuytren's disciples used
multiple open wounds, operating in an era of unconfined suppuration and the anticipated
drainage of laudable pus. Without the benefits of asepsis or antibiotics, this procedure was
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associated with significant mortality and morbidity. Another prominent French surgeon,
Guillaume Goyrand, advocated the use of longitudinal incisions and open fasciotomies,
while fifty years later William Adams appears to have pioneered the combination of postoperative splinting with a closed subcutaneous fasciotomy technique in an attempt to
reduce post-operative infection (Adams, 1885; Goyrand, 1833).

Open operations did not become safe until the advent of antisepsis (following the work of
Pasteur and Lister) and later developments of aseptic surgical technique. Fasciectomy,
performed under general anaesthetic and tourniquet control, has subsequently supplanted
fasciotomy as the operation of choice, although recent success without tourniquet and
performed under local/regional anaesthetic will add a new dimension following the work
of Lalonde of Toronto (Lalonde and Martin, 2014).
1.3.1 Limited or partial fasciectomy
Operating on only those areas of palpable fibrosis or contractures involving the small
joints, dissection can be restricted to involved tissues that are safely excised through
longitudinal incisions and under tourniquet. This approach has been widely favoured and
recommended (Hamlin, 1952; Heuston, 1969; Skoog, 1963). Apart from some variations
in operative and post-operative splinting, this operation is still the surgery of choice today
(Hindocha, Stanley, Watson, & Bayat, 2006; Shih and Bayat, 2010). By avoiding or
limiting dissection into normal tissue planes one avoids excessive scar tissue formation
which inevitably transforms to Dupuytren’s tissue and results in recurrence (Bayat &
McGrouther, 2006).
1.3.2 Dermofasciectomy
Sacrifice of skin is only contemplated when considered necessary to adequately remove
underlying adherent Dupuytren’s tissue. It generally becomes an issue during the course
of operation for recurrent disease. Extensive involvement of the palmar skin with
adherence to underlying fibrosis sometimes necessitates excision of the skin and
replacement with a full-thickness skin graft (dermofasciectomy). This technique was
introduced by Maccallum in 1962 (Maccallum & Hueston, 1962) and has proved effective
in reducing further recurrence (Hueston, 1984).
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1.3.3 Z-Plasty repair
The use of Z-plasties in repair of the skin incision has three main objectives: to assist in
closure with adequate skin cover by rearrangement of flaps and lengthening the wound;
to avoid a longitudinal scar across skin creases which may lead to scar contracture; and
thirdly to realign the subcutaneous tissue and thereby reduce the chance of recurrence of
contracture (Baker & Watson, 1980).
Radical or total fasciectomy radical dissection of Dupuytren’s affected subcutaneous
tissue across the palm is rarely performed. McFarlane has advocated an extensive removal
of involved and potentially involved digital and palmar fascia (McFarlane, 1990), based
on his description of three different types of cords found in relation to normal anatomical
structures in the palm. Apart from being unnecessary in most cases, it implies removal of
potentially normal tissue including the palmar aponeurosis. This surgery is also timeconsuming with the other disadvantage of a high recurrence rate (Clarkson, 1963).
Selective dissection along affected bands of Dupuytren’s while preserving normal
anatomy is much preferred. Luck and other authors who have reported extensive
dissections have removed only involved fascia rather than perform a prophylactic
fasciectomy (Luck, 1959; McIndoe & Beare, 1958; Iselin, 1955; McGregor, 1985;
Hueston, 1961; McCash, 1964).

1.3.4 Amputation
Considered as a last resort following failed attempts at release of debilitating digital
contractures, amputation must be thought of as an acceptable means of restoring a
functional grip. The difficulty in straightening the proximal interphalangeal joint,
particularly in the little finger, was appreciated by Dupuytren in 1831. Since then there
have been numerous operations proposed in an effort to avoid amputation, including
proximal interphalangeal joint arthrodesis or arthroplasty, division of flexor tendons, and
wedge osteotomy of the proximal phalanx (Moberg, 1973), generally associated with postoperative extension splinting (Ebskow et al., 2000; Larson and Jerosch-Herold, 2008).
Amputation would be an appropriate option, however, if the complications of a useless
15

finger are to be avoided and vascularized dorsal skin flaps can be utilized to replace
involved skin on the adjacent palm (Tonkin, 1984).
1.3.5Percutaneous division of fibrous cords
This blind technique (to be distinguished from the open fasciotomy advocated by Astley
Cooper in 1822) involves the use of a bevelled needle or fine scalpel to release a
contracture, usually at metacarpo-phalangeal level, where a reasonably thin cord of
Dupuytren’s can be palpated beneath the skin. Closed fasciotomy is almost confined to
solitary contractures in the early stages of disease or in elderly patients who may not
withstand more extensive surgery, as it can be performed under local anaesthetic. This
minimally invasive procedure has good short-term results in mild or moderate
contractures with a very low complication rate (Rowley et al., 1984; Foucher et al., 2003;
Van Rijssen et al, 2006). While it may be considered a temporary measure (Van Rijssen
& Werker, 2006), this approach is rarely considered appropriate in developing or
progressive disease (Shaw et al., 1996). There are limited published data comparing
medium-term outcomes of fasciectomy and closed percutaneous fasciotomy, but
adherents to the latter procedure are aware of the complications involving skin tears and
prolonged healing with frequent early recurrences.
1.4 Non-surgical treatment of Dupuytren’s disease
1.4.1 Physical manipulation of Dupuytren’s contracture
Traumatic extension with rupture of fibrous cords responsible for digital contractures in
Dupuytren’s disease was found to provide immediate though painful release of a flexion
deformity (Hawkins, 1835). When performed as an elective procedure under anaesthetic
the excessive force required by passive extension is quite traumatic. Used in conjunction
with percutaneous section of the cords there is increased likelihood of skin dehiscence
with the problem of prolonged healing and no lasting benefit (Colville, 1983).

A similar outcome results from sustained splinting with gradually increasing traction to
release a flexion contracture. Where release of the contracture has apparently been
successful there is almost universal evidence of recurrence within weeks of removal of
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the traction apparatus (Shaw et al., 2007). Although it becomes an essential stage in the
management of contractures by injection, physical manipulation per se is therefore no
longer recommended to treat contractures due to Dupuytren’s disease (vide infra).
1.4.2 Irradiation
As a non-surgical intervention radiotherapy has been trialled in early-stage Dupuytren’s
disease to reduce fibroblast activity (Keilholz et al., 1996). An estimated 87% of patients
reported a subjective relief of symptoms while symptomatic cords and nodules were
reduced in 75% (Seegenschmiedt, Olschewski, & Guntrum, 2001). Long term results in
one study showed no progression of disease after thirteen years (Betz et al., 2010). Apart
from some minor late toxicity in the form of localized skin atrophy in 32% of cases, this
would appear to be safe practice with no major complications. Significantly there has been
no evidence of radiation-induced malignancy, contrary to early experience with exposure
to X-rays. Whilst the results reported in the few studies on irradiation therapy have been
positive, this treatment modality has not been widely adopted. The positive results are
potentially due to the treatment of patients at a very early stage of localized disease
development. Only a few patients present for medical advice at this early time, when
surgery would not be considered as an option.
1.4.3 Extracorporeal shockwave therapy
Knobloch and others hypothesized in 2010 that focused extracorporeal shock wave
therapy may be used as a non-invasive method of reducing palmar fibromatosis and
progressive contractures in Dupuytren’s disease, on the basis of positive results obtained
from a randomized-controlled trial in the management of Peyronie’s disease (Knobloch et
al., 2011). The outcome of a similar trial with Dupuytren’s individuals suggests that this
therapy may be useful in preventing or slowing the rate of contracture (without major
complication), but long-term follow-up has not been reported.
1.5 Pharmacological treatments of Dupuytren’s disease
Other non-surgical or medical treatments have been attempted with variable degrees of
success. Their rationale is based on the possible reversal or interruption of cellular activity
17

of abnormal myofibroblasts in Dupuytren’s tissue and the removal or prevention of the
excessive collagen deposition characteristic of this disease. Such treatments might
therefore be expected to have some beneficial effect through direct or indirect limitation
of collagen deposition, thereby limiting disease progression. They include: injection of
steroid, interferon or collagenase; ingestion of vitamin E, allopurinol or verapamil; Bassot
(1965) and later Hueston advocated ‘enzymic fasciotomy’ as an alternative to surgery, but
their results were not rewarding (Bassot, 1965; Hueston, 1974).
1.5.1 Intralesional steroid injection
The effect of steroids on Dupuytren’s disease has been investigated with reference to the
role of programmed cell death; the progress of Dupuytren’s disease is seen as an
imbalance between fibroblast activity and apoptosis. Both in vivo and with cultured
Dupuytren’s cells, steroids were shown to increase the rate of apoptosis and to decrease
rates of proliferation when compared with control fibroblasts (Meek et al., 2002).
1.5.2 Intralesional collagenase injection
Somewhat better results have followed various clinical trials using Clostridium
histolyticum collagenase injections with release of limited contractures in the early stages
of disease (Badalamente et al., 2002; Hurst et al., 2009). In America Clostridium
histolyticum collagenase was approved by the FDA in February 2010 for use as an
injectable treatment for Dupuytren’s disease (Shih & Bayat, 2010). Injection is followed
by manipulation and attempted release of contracture after forty-eight hours. Results to
date have been variable and outcomes depend heavily upon case selection, clinical
expertise and patient compliance. Reliable longer-term recurrence rates have yet to be
determined.

1.5.3 Intralesional gamma-interferon
Pittet et al. (1994) tested the effect of Gamma-Interferon injected into Dupuytren’s tissue,
and also hypertrophic scars (Pittet et al., 1994). Gamma-interferon has been shown to
decrease fibroblast replication, alpha smooth muscle actin expression and collagen

Investigating the Molecular Pathology of Dupuytren’s Disease

production. Some decrease in lesion size has been observed in hypertrophic burn scars
and Dupuytren’s nodules with no significant release of contractures.

Although there is some advocacy in recent years for pharmacological and other minimally
invasive treatments as temporary or palliative control of limited fibrosis in selected cases
of Dupuytren’s disease, none of these methods has been adopted universally as alternative
treatment on a routine basis.
1.6 Summary
In summary, the primary treatment modality for Dupuytren’s disease is currently surgical
intervention, with removal of the cord tissue, release of debilitating contractures and
salvage of normal surrounding tissue. This has been effective also in slowing the
progression of Dupuytren’s disease in many cases, but the progressive nature of the
disease can lead to recurrence and continued disability. There are also potential risks
inherent in the surgical procedures, most notably associated neurovascular trauma that can
be avoided by careful dissection, and scar contractures that are often painful. Sympathetic
dystrophy as a complication of hand surgery is disabling, inexplicable, resistant to
treatment and fortunately rare.

Other conservative treatment options, predominantly pharmacological, have been
developed and are subject to clinical controlled trials, long-term follow-up and
assessment. These have generally shown limited efficacy, at least in part due to an
incomplete understanding of the molecular pathology. In a recent review of surgical and
medical advances in the management of Dupuytren’s disease (Mafi et al., 2012) the
authors have emphasized the importance of genetic studies in elucidating the cause of the
disease with the prospect of preventing its progression.
In line with current understanding of the clinical progression and treatment of Dupuytren’s
disease therefore, there is reason to believe that further elucidation of its molecular
pathology and aetiology might result in new treatments and potentially improved
outcomes.
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1.7 The Epidemiology of Dupuytren’s disease
Dupuytren’s disease is generally uncommon before the age of forty-five. Although the
age at which palmar fibromatosis in adults first becomes apparent can be difficult to
establish, the average age of onset is generally accepted as being 50+/- 5 years for males
and 55+/- 5 years for females (Hindocha et al., 2006). Beyond the age of fifty years the
prevalence of Dupuytren’s disease in any population study increases with age until about
80 years, when it tends to plateau (Early, 1962; Khan et al., 2004). There is a definite
gender bias, generally accepted as approximately M:F = 6:1 in the 60-70 year age group,
with variable figures beyond this age, but the observed convergence of male and female
incidence after eighty years could be due to a combination of population changes,
hormonal imbalance and the variable effects of age-related comorbidities and lifestyle
factors.

Ageing itself could be instrumental in progressing the fibromatosis as with other
neoplasms, possibly related to diminishing immune response and nuclear/chromosomal
fragility. Specific neurovascular changes have not been identified in Dupuytren’s tissue,
but could become secondary factors in the activity of fibroblasts as relatively avascular
collagen deposits accumulate. With an ageing population raised triglyceride levels,
hypercholesterolaemia and hypertension as well as Dupuytren’s disease become more
prevalent - to date there is nothing to suggest that there is any common causal relationship.
The possible role of associated conditions in the aetiology of Dupuytren’s palmar
fibromatosis has received much attention in world literature (P. Burge, Hoy, Regan, &
Milne, 1997; P. D. Burge, 2004; Gordon, 1954; Hindocha, Stanley, et al., 2006;
Mackenney, 1983; Carson and Clarke, 1993; Loos et al., 2007) Associated conditions
referred to include: diabetes mellitus, osteoarthritis, hypercholesterolaemia, hypertension,
and gout, all of which are closely related to ageing.
The relevance of some of these factors to the aetiology of Dupuytren’s, including alcohol
abuse, epilepsy, hypercholesterolaemia, hepatic cirrhosis, smoking and diabetes mellitus,
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has been questioned (Carson and Clarke, 1993; Schiavon et al., 2004; Loos et al., 2007)
The association of Dupuytren’s with epilepsy is uncertain (and denied by some authors on
a statistical basis; Mackenney, 1983) but the highest prevalence rate was reported in a
study group of adult epileptic patients in the United Kingdom (56%, 1976). However there
is a huge discrepancy with other similar studies (eg Germany, 20% and France, 9%;
Hindocha, McGrowther and Bayat, 2009). Whilst there are a number of links associating
the presence of Dupuytren’s disease with other conditions, to date no causative links
between Dupuytren’s disease and other pathologies has been established, and in fact
ageing may be the common link between the diseases rather than any specific molecular
pathology.
1.7.1 Epidemiological evidence for a genetic component to Dupuytren’s disease.
Dupuytren’s disease is most common in Caucasian adults of Northern European ancestry
(Bayat and McGrouther, 2006). Various surveys have been published to report the
occurrence of Dupuytren’s disease among other ethnic communities; African Americans
(Gonzalez et al., 1998; Mitra & Goldstein, 1994; Sladicka et al., 1996) Chinese-oriental
(Egawa et al., 1990) Japanese (Abe et al., 2007); African (Makhlouf et al., 1987; Mennen,
1986; Muguti & Appelt, 1993; Richard-Kadio et al, 1997); Icelandic (Gudmundsson et
al., 2000); Chinese (Liu & Chen, 1991); Thai (Vathana et al., 1990) and Indian (Srivastava
et al., 1989) populations as well as Eastern European and Mediterranean cohorts (Zerajic
& Finsen, 2004), with varying rates of incidence in these different populations. The ethnic
influence becomes more apparent when migrant populations from Poland or Scandinavia
examined in America are found to show similar rates of disease as found in their countries
of origin (Soboeiro, 2000), suggesting the importance of genetics rather than environment
in the incidence of Dupuytren’s disease. Nevertheless, environment is also likely to play
a role, as evidenced by the study of Finsen and colleagues (2002) who studied two ethnic
groups in northern Norway. Without identifying specific factors that might influence the
occurrence of Dupuytren’s, the findings showed that family members were more likely to
develop Dupuytren’s disease if they lived in the same geographic area as their affected
relatives.
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Despite the many studies linking Dupuytren’s disease to other environmental factors,
family history is undoubtedly one of the strongest predictors of susceptibility. This clearly
demonstrates that there is a substantial genetic influence on the development of
Dupuytren’s disease. The inheritance pattern of Dupuytren’s disease was studied by
Burge, who reported:
“Characterization of autosomal dominant inheritance in this condition is reinforced by the
occurrence of affected individuals, both male and female, in consecutive generations, with
evidence of transmission female to male, and variations in degrees of penetrance,” (Burge,
1999). The more recent ‘Rejkavik Study’ reported by Gudmundssen and colleagues that
recorded a large Icelandic family pedigree with affecteds in three generations, reached
similar conclusions (Gudmundsson et al., 2000). Therefore strong evidence exists for a
significant genetic component to the occurrence of Dupuytren’s disease. Understanding
the key genes that underpin this link will be important to understand the disease and
ultimately to develop better treatments.
1.8 The Molecular and cellular pathology of Dupuytren’s disease
Dupuytren’s disease involves progressive, increasing deposition of stable collagen and
extracellular matrix proteins, with subsequent contracture of the matrix through the
activity of fibroblast subpopulations. Whether the increased density of the matrix is caused
by excessive production or reduced degradation is as yet unclear, and the molecular
signals that trigger this process unknown. There is some evidence that the immune system
is important in Dupuytren’s disease, whilst other studies suggest that innervation and
neuroinflammatory mediators may be involved. Nevertheless, whilst the molecular and
cellular triggers remain difficult to elucidate, the progressive increase in extracellular
matrix and subsequent contraction clearly involves myofibroblasts (Gabbiani & Majno,
1972). This section will review the evidence and possible roles of different cells and
systems in the pathology of Dupuytren’s disease.
1.8.1 The role of myofibroblasts in Dupuytren’s disease
The cellular structure and biology of the myofibroblast were elucidated by Gabbiani,
Majno and Ryan (Gabbiani & Majno, 1972; Gabbiani et al., 1973), and others (Tomasek
and Haaksma, 1991; Tomasek et al., 1999; Skalli and colleagues, 1989). The contractile
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mechanisms of the myofibroblasts in Dupuytren’s disease were first investigated by
Badalamente and colleagues in relation to the pathogenesis of contractures in this disease
(Badalamente et al., 1983). Factors involved in the differentiation of these cells at a
molecular level and the activation of their innate contractility in the progression of
Dupuytren’s disease have been further studied by Verjee et al. (2013).
Connective tissue contracture as occurs in Dupuytren’s pathology is “a sustained, lowenergy shortening process which involves matrix-dispersed cells and is dominated by
extracellular events such as matrix remodeling” (Tomasek, 2002; Glimcher & Peabody,
1990). Histological examination of Dupuytren’s tissue readily confirms the relative
hypocellularity in a dense matrix of collagen in established disease. Multinucleated cells
have been observed in all clinical stages of progressive fibromatosis. Whether due to
fibroblast fusion or nuclear division without cytokinesis, the fact that multinucleated
fibroblasts can originate via different mechanisms may influence their behaviour in
various conditions including in vitro culture assays and in certain fibroblastic pathologies
such as foreign body response, fibrosis, cancer and aged tissue (Holt and Grainger, 2011).
In Dupuytren’s disease, as in normal wound healing, collagen type I is largely replaced
by type III collagen which is known to be present in remodeling tissues, or in normal
tissues that are subject to mechanical stress (Gabbiani et al., 1976). The remodeling, which
is an essential element in the progressive shortening process of contracture formation,
involves removal of matrix molecules and is largely mediated by metalloproteinases
which allow slippage and re-apposition of adjacent fibrils.

It is thought that the contractile force generated by myofibroblasts translates into collagen
network shortening through fibronexus adhesion complexes that are linked to intracellular
stress fibres. These factors (stress fibres and adhesion complexes with the extracellular
matrix) are distinctive features for differentiated myofibroblasts. These cells generate
sustained contractile force, which is generated by contractile stress fibres composed of
bundles of actin microfilaments with associated non-muscle myosin and other actinbinding proteins. The production of matrix and subsequent response to the matrix to
trigger contraction is critical to the pathology of Dupuytren’s disease.
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Under mechanical stress, fibroblasts can undergo a two-stage differentiation process
(Figure. 1.3). The fibroblasts first differentiate into proto-myofibroblasts, which form
cytoplasmic actin-containing stress fibres that terminate in fibronexus adhesion
complexes (Tomasek et al, 1991; 2002). Proto-myofibroblasts also express and organize
cellular fibronectin at the cell surface and are capable of generating contractile force. The
combination of transforming growth factor 1 (TGF-1) with cellular fibronectin and
continued mechanical tension facilitates the final stage in formation of the differentiated
myofibroblast (Fig. 1.3). Therefore it is likely that during the initiation and progression of
Dupuytren’s disease the initial mechanical stress triggers fibroblast differentiation and
production of TGF-1, leading to increased mechanical stress and subsequently a negative
cycle of increased matrix production, fibroblast differentiation to myofibroblasts and
contraction This cycle of degradation and production of the matrix leads to shortening and
contracture (Fig. 1.4).

.
Figure 1.3 Two stage model of myofibroblast differentiation

Mechanical tension and the

expression of specific growth factors lead to fibroblast differentiation into myofibroblasts. Increasing myofibroblasts
increases tension and propagates the transition (from Tomasek et al., 2002).
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Fig. 1.4 Mechanism of contracture in Dupuytren’s disease
(as described in Tomasek et al, from Ketchum LD, 2014)

1.8.2 The role of the immune system in Dupuytren’s disease
The possibility of Dupuytren’s being a T-cell mediated autoimmune condition has been
proposed and the finding of increased numbers of DR+ T-cells in the circulation may
support an immunological mechanism in its pathogenesis (Gudmundsson et al 1998). The
role of the highly polymorphic human leucocyte antigen (HLA) has also been
investigated, particularly in relation to genetic susceptibility to develop fibromatosis
(Gudmundsson et al., 1998). A significant association between affected patients and HLADR3 and autoantibodies to proteins contained in the extra-cellular matrix (elastin and
collagen types 1-4) suggests a correlation with the process of remodelling during the
course of fibrosis (Neumuller et al., 1994).

McCarty and colleagues have explored the immunogenetic component of this condition
and published a review of previous studies (McCarty et al., 2010). These authors
concluded: “There is a clear association with specific HLA alleles and predilection or
protection to Dupuytren’s disease. In particular, the class II HLA-DR locus is the most
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promising region for a biomarker of Dupuytren’s disease. The ability to accurately
perform an assessment of an individual’s potential immunogenetic susceptibility to
Dupuytren’s disease may potentially lead to a more personalized approach to their
diagnostic, therapeutic and prognostic management in the future”.
More recently, a characterization of the cells present in Dupuytren’s tissue using
immunohistochemistry found signiﬁcant numbers of immune cells, including classically
activated macrophages. High levels of proinﬂammatory cytokines (eg tumour necrosis
factor, TNF) were also detected in tissue from Dupuytren’s patients (Verjee et al., 2013).
Verjee et al. also demonstrated a link between TNFa and the differentiation of fibroblasts
into myofibroblasts, particularly in cells isolated from Dupuytren’s tissue. This suggests
that the microenvironment may influence fibroblast phenotype, and that these changes
could be mediated by the immune system. These studies indicate that the immune system
may play an important role in the etiology and pathology of Dupuytren’s disease.
However, whilst inflammation has a strong link to fibrosis during wound healing, the
mechanistic link between immune activation and Dupuytren’s disease is not clear. Many
of these observations may be indicative of immune responses rather than drivers of the
disease, and the potential importance of other mechanisms cannot be overlooked.
1.8.3 A role for vascular and innervation changes in Dupuytren’s disease
The search for control factors that may influence the growth and activity of myofiboblasts
and the production of collagen in the extracellular matrix has provided an important focus
for extensive laboratory investigations over the closing decades of the 20th century.
Morphological evidence consistent with localized microvascular ischaemia (Hussl, 1979;
Maccallum & Hueston, 1962; Murrell & Hueston, 1990) in Dupuytren’s tissue has been
observed.

Murrell and colleagues (Murrell et al., 1987; Murrell et al., 1989) also showed that
superoxide free radicals and hydroxyl radicals, which are produced during the metabolism
of adenosine triphosphate to xanthine and uric acid, are released in Dupuytren’s tissue. “A
six-fold increase in the concentration of hypoxanthine in Dupuytren’s tissue and in the
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activity of xanthine oxidase have been demonstrated and these have a stimulatory effect
on the proliferation of fibroblasts” (Thurston, 2003). These findings are significant in light
of the strong association between Dupuytren’s disease and gout, diabetes mellitus and
smoking, with their inherent metabolic and peripheral vascular changes known to be
associated with these diseases. In particular the link between Type II diabetes mellitus and
the incidence of Dupuytren’s disease suggests the peripheral vascular changes may be
important in this disease. Other studies have clearly shown that vascular changes can
influence fibroblast phenotype (Misra et al., 2010; Watson et al., 2014), with hypoxia
leading to a more myofibroblast phenotype and likely to be important in fibrosis in at least
some tissue types. However, to date the evidence in Dupuyren’s disease is associative
rather than causative, and no clear studies have demonstrated a link between changes in
vascular function and Dupuytren’s pathology.
1.9 Evidence for candidate susceptibility genes in Dupuytren’s disease
Identification of proteins/genes important in Dupuytren’s disease has largely been focused
on two approaches. One is the identification of genes associated with Dupuytren’s disease
through standard genetic approaches. The other is the proteomic or transcriptomic analysis
of disease tissue compared to control tissue (commonly in the same patients). Both these
approaches provide an opportunity for insight into the molecular pathology of the disease,
but to date no conclusive evidence for the mechanism of induction of Dupuytren’s disease
or the specific mutations involved has been generated.

As early as 1984 Iwasaki and colleagues studied the histopathology of Dupuytren’s
disease and concluded that growth factors induce proliferation of genetically abnormal
myofibroblasts (Iwasaki et al.,1984). Subsequently, the studies of Baird (Baird et al.,
1993) among others have implicated transforming growth factor  (TGF) cytokines and
receptors in the regulation of cell proliferation, migration and differentiation, and
therefore as a major factor in the pathogenesis of Dupuytren’s disease (Alioto et al., 1994;
Badalamente et al., 1996; Berndt et al., 1995; Kloen et al., 1995; Tomasek et al., 1999).
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These receptors were therefore seen to represent candidate susceptibility genes for
Dupuytren’s disease and were submitted to further investigation (Bayat et al., 2003). A
statistically significant difference in genotype frequency distributions between cases and
controls for TGFR1 polymorphisms in the recessive model was observed in these studies.
The genotype or allele frequency distributions for other TGF receptors were not
significantly different between controls and Dupuytren’s patients. Their conclusion
therefore, was that Dupuytren’s appears to be a complex oligogenic condition in which
the TGF signaling system plays an essential role. From a more recent study by Zhang et
al. a gene expression analysis of Dupuytren’s cord tissue, over twenty unique genes
(including several previously reported) were identified and found to be significantly
upregulated, ie expressed uniformly at much higher levels than in the controls (Zhang et
al., 2008). Shih et al. (2009) performed similar genetic studies for identification of
biomarkers in Dupuytren’s tissue by comparative analysis with non-specific fibroblasts
(Shih et al., 2009) while differentially expressed genes were identified in fibroblasts from
Dupuytren’s tissue by Satish and colleagues (Satish et al., 2011). While increased
expression of these genes suggests that they play a role in the disease process it is not clear
if this is promoting the disease or a response to ameliorate the fibrosis.

Genetic approaches have led to the idenfication of several chromosomal regions thought
to be associated with Dupuytren’s disease. One of the earlier genetic studies reported
mapping of an autosomal dominant gene for Dupuytren’s to chromosome 16q in a
Swedish family (Hu et al., 2005; Shih et al., 2011). However, this has not been supported
by more recent investigations.

Shih et al. also noted the potential role for Matrix Metalloproteases (MMPs) and the Wnt
signalling pathway in Dupuytren’s disease (Shih et al., 2012). This is supported by the
findings of a large genome-wide association study (GWAS) into the genes associated with
Dupuytren’s disease (Dolmans et al., 2011; Ojwang et al., 2010). This study, reported in
the New England Journal of Medicine, involved a GWAS of 960 Dutch persons with
Dupuytren’s phenotype and 3117 controls, to test for association between the disease and
genetic markers. Nine different loci involved in genetic susceptibility to Dupuytren’s
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disease were identified, six of them found to harbour genes encoding proteins involved in
the Wnt-signalling pathway. This finding strongly suggests that aberrations in this
pathway are key to the process of fibromatosis in this disease. However, whilst this data
is convincing again the functional data linking the genes identified with Dpuytren’s
disease remains lacking, and whilst Wnt signalling is known to be important in fibrosis
(Piersma, 2015), again there is limited data directly linking specific genes within this
pathway or mutations in specific genes to Dupuytren’s disease. Other signalling pathways
such as the ‘sonic hedgehog pathway’ and the ‘TGF signalling pathway’ are also known
to involve genes that are linked to Dupuytren’s development and progression of fibrosis
(Fig.1.5), and are thought to converge and result in fibroblast to myofibroblast transition,
thus promoting the progression of Dupuytren’s disease (Fig.1.5).

Figure 1.5 Signaling pathways with evidence of involvement in Dupuytren’s disease
WNT, TGF and Mechanotransduction pathways have all been implicated in the pathogenesis of Dupuytren’s
disease through genetic, molecular and cellular studies (taken from Musumeci M et al, 2015)

Unravelling the signalling pathways promoting fibrosis in Dupuytren’s disease has
revealed TNF (tumour necrosis factor) as the only pro-inflammatory protein mediator
(cytokine) to selectively convert normal fibroblasts from the palm of patients with
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Dupuytren’s disease into myofibroblasts via the Wnt signalling pathway (Verjee et al.,
2013). The same authors reported reversal of the myofibroblast phenotype by blockade of
TNF (by reducing expression of alpha smooth muscle actin and inhibiting contractile
activity of myofibroblasts) and concluded that TNF inhibition may be considered a
therapeutic target in the prevention of progression or recurrence of Dupuytren’s disease.

From analysis comparing fibroblasts with disease-specific phenotype from tissue biopsies
to control cells Shih et al. found 25 candidate genes, further short-listed to six genes via
functional annotation, and subsequently identified ADAM12, POSTN and TNC as
potential biomarkers for Dupuytren’s disease. The review by same authors showed two
genes highlighted by both gene-expression profiling and whole genome association
studies – MAFB and PRKX (a sex-linked protein kinase), whilst MAFB has also been
associated with Dupuytren’s disease in another study (Lee et al., 2006).

Tissue studies for gene expression in fibroblasts have also been used to demonstrate
transcription profile differences between Dupuytren’s disease and normal control
fibroblasts (Forrester, 2013). Results indicate that in Dupuytren’s disease there is an
excess of collagen and other ECM that is not controlled due to a reduction in matrix
metalloproteinases and other matrix remodelling proteins (Shih, 2009; Forrester, 2013).
A reduction in the fibrotic control protein, follistatin, may also contribute to development
of Dupuytren’s disease (Forrester, 2013). In summary, there have been a number of studies
investigating the molecular pathology and genetics of Dupuytren’s disease. Whilst many
of the studies have small sample numbers and limited power, the same consistent themes
have emerged over time. A role for Wnt signaling has been supported in many genetic and
expression-based studies, whilst the TGF pathway has also been heavily implicated, as
in many other fibrotic diseases (Shih, 2012, Fig. 1.5)). Nevertheless, there remains a gap
in the knowledge to demonstrate the molecular pathogenesis of Dupuytren’s disease.
Genetic approaches remain one of the most likely options to progress our understanding
of this disease.
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Fig. 1.6 Summary of pathways and genes implicated in Dupuytren’s disease
(Taken from genetic and molecular/cellular biology studies (from Shih, Watson and Bayat, 2012))

1.10 Summary
Despite many years of investigation into the molecular and genetic factors that may be
important in Dupuytren’s pathology, no clear mechanism has yet been described to
explain the triggers that lead to Dupuytren’s fibrosis. The use of disease tissue is limited
by the difficulty of identifying responsive and causative changes, whilst genetic studies to
date remain inconclusive without the necessary additional functional validation. Therefore
there is a need for further investigation into the possible causes of Dupuytren’s disease at
the molecular and genetic level. Understanding the triggers and key pathways that are
important in Dupuytren’s disease will be critical to change the treatment paradigm from
one of symptom limitation to disease prevention. In this thesis, different genetic strategies
have been used to identify genes that may be important in the pathogenesis of Dupuytren’s
disease in the Western Australian population. The clear genetic basis for the disease in
specific families provides an opportunity to identify causative rather than responsive
genes involved in the pathology. Therefore the first study was to investigate potential
causative mutations in an individual Western Australian family with inherited
Dupuytren’s disease.
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Hypothesis
That heritable Dupuytren’s disease is caused by a non-synonymous mutation leading to
defective protein function and the onset of palmar fibromatosis.

Aims
1.

To use whole exome sequencing (WES) of a Western Australian family with

autosomal dominant inheritance of Dupuytren’s disease to identify putative causative
mutations.

2.

To investigate the presence of the putative mutations in a wider population-based

cohort of people with Dupuytren’s disease.

3.

To evaluate the putative mutations from Aims 1 and 2 in unrelated individuals

with Dupuytren’s disease.

4.

To investigate the functional consequences of the putative mutations identified in

Aims 1-3 on fibroblast phenotype and pathobiology with relation to Dupuytren’s
disease.
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CHAPTER 2
Aim 1.To use whole exome sequencing (WES) of a Western Australian family with
autosomal dominant inheritance of Dupuytren’s disease to identify putative causative
mutations
.

2.1 Introduction
The genetic defects underlying inherited traits have traditionally been investigated
using linkage analysis. This technique involved the use of microsatellite markers
located throughout the genome and found in linkage disequilibrium as the basis for
identifying regions inherited in affected individuals within a family and not in those
that were unaffected, ‘linking’ the causative defect to the regions identified
(Chistiakov et al., 2006). In the case of Dupuytren’s disease, a previous linkage study
has been performed in a Swedish population and suggested an important region was
located on Chromosome 16. The single region identified was approximately 30cM in
size, bound by markers D16S3131 and D16S514 with a LOD score of >1.5. The LOD
score was improved to LOD 3.18 when two affected cousins were genotyped with
additional microsatellite markers, supporting linkage to the region on chromosome 16
(Hu et al., 2005). However, traditional linkage studies such as this have been limited
by low resolution and an inability to progress to identification of specific genes of
interest.

More recent approaches using single nucleotide polymorphisms (SNPs) as markers
throughout the genome (of which >2 million have been identified) to identify regions
of interest have provided much higher resolution and greater ability to identify gene
mutations involved in disease (Stranger et al., 2011). These studies, however, are still
not optimal and significant challenges in identifying causative mutations and
functional data nevertheless remain (Edwards et al., 2013).
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One large population study reported in the New England Journal of Medicine
identified nine possible Dupuytren’s disease-associated loci on three different
chromosomes (7, 19 and 22), in a GWAS involving 960 Dupuytren’s patients and
over 3000 controls (Dolmans et al., 2011). Six of the nine associated loci were found
to harbour genes encoding proteins involved in the Wnt-signaling pathway. However
no functional evidence supporting a role for the Wnt-signaling pathway or identified
genes was provided, and the presence of multiple other genes residing in the identified
regions leaves doubt as to the relative importance of Wnt-signaling to Dupuytren’s
pathology.

An alternative approach that has recently been used in studies of inherited disease
within families is the use of whole exome sequencing (WES) (Rabbani et al., 2014).
This approach involves sequencing the part of the genome encoding for proteins to
identify varaints that are likely to affect protein function and therefore underlie
disease. This approach is limited in that only functional variants (rather than those
affecting expression levels, for example within promoter regions) can be identified.
However, many disease-causing variants (mutations) have been identified using this
approach, which has the significant advantage over GWAS methodology in actually
identifying variants in specific genes that can be further characterized (Bao et al.,
2014; Rabbani et al., 2014).

Here, we have used WES in four members of a Western Australian family with
autosomal dominant Dupuytren’s disease. The four members of the family initially
sequenced were all affected individuals with Dupuytren’s disease. Heterozygous,
non-synonymous variants present in all 4 individuals were identified. These variants
were subsequently investigated using PCR in other affected and unaffected members
of the family to determine those most likely to underlie the Dupuytren’s pathology.
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2.2 Methods
2.2.1 Ethics Approval
All human studies complied with the National Health and Medical Research Council
statement on ethical conduct of human studies and were approved by the Notre Dame
Human Research Ethics Committee. All participants received a patient information sheet
and had any questions answered by Dr Pearce prior to providing informed consent
(Appendix 1).
2.2.2 Participants
Members of a family related to a previous patient of Dr Pearce who had been identified
as having Dupuytren’s disease were identified and examined for phenotypic evidence of
Dupuytren’s disease by Dr Pearce. Related siblings, children of a second generation and
spouses by marriage were included (Fig. 2.1). All members were interviewed and
examined by Dr Pearce for the presence of Dupuytren’s disease. DNA was collected from
all consenting participants.
2.2.3 Saliva collection for genomic DNA isolation
Sputum samples were collected from fifteen members who were clinically diagnosed with
Dupuytren’s disease and from eight non-affected family members (Figure. 2.1) using
Oragene saliva collection kits (DNAGenotek) and stored at 4 oC until DNA was isolated.

Figure 2.1: Deindentified family pedigree of family with autosomal dominant inheritance of Dupuytren's disease

Affected family members are highlighted with red, unaffected samples are completely white. Deceased
family members have a strikethrough symbol as per standard representation.
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DNA samples were collected from 23 members of the family including affected and
non-affected individuals. Red indicates affected individual with clinical diagnosis of
DD.
2.2.4 DNA isolation protocol
DNA was isolated using the manual purification protocol (as per manufacturer’s
instructions). This procedure produced a median yield of 110µg of DNA from 2ml of
saliva collected in a 4ml Oragene saliva collection tube.
2.2.5 DNA quantitation
DNA samples were quantified using a Nanodrop spectrophotometer (ND-1000,
Thermoscientific Instruments). For each sample a 1l aliquot was removed and DNA
concentration calculated.
2.2.6 Whole exome sequencing (WES)
2.2.6.1 SOLiD Platform

WES was initially performed for 2 affected and one unaffected family member (D3, D12,
D18, Fig. 2.1) at the Lotterywest State Biomedical Facility Genomics (LSBFG) node
(Perth, Western Australia) in a previously described method (Ravenscroft et al., 2013).
Sonication was used to fragment 3μg of DNA from each individual; DNA was fragmented
by and ligated to sequencing adaptors (SOLiD). Exomic sequences were enriched from
the resulting libraries (SeqCap EZ Human Exome Library v2.0 exome capture system;
Nimblegen, Roche Diagnostics). Sequencing was performed using a 5500XL SOLiDTM
system (Applied Biosystems). After alignment the exomes were covered to >20-fold for
at least 80% of the targeted sequence.
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LifeScopeTM 2.5 (Life Technologies) was used to call variants against the GRCh37
human reference genome, which were subsequently filtered using ANNOVAR (Wang
et al., 2010). Filtering included exclusion of variants in the 1000 Genomes database
(Clarke et al., 2012) if variants had a minor allele frequency greater than 1%, and
removal of SNPs in the dbSNP135 common database.
2.2.6.2 Ion Proton

A second whole exome sequencing approach was next undertaken using the Ion ProtonTM
platform (Ampliseq chemistry, Life Technologies) and was also performed at the LSBFG,
as previously described (Todd et al., 2015). Four affected family members (D4, D6, D8,
D31) were processed with this technique. Twelve PCR pools were used to create libraries
from 100ng of DNA from each individual. Libraries were purified and amplified for two
rounds using AMPure beads (Beckman Coulter) and Platinum® High-Fidelity Taq
Polymerase respectively. An Ion Proton™ Template 200 v3 kit was used to attach Ion
Sphere™ Particles to the libraries (diluted to 18-26pM). Sequencing was performed using
a P1 sequencing chip with an Ion Proton sequencer™.

All exomes were covered to >20-fold for >90% of the targeted sequence. Sequence
variants were analysed using in-house scripts, again based on ANNOVAR software.
Variants were excluded if they appeared at a frequency of >0.5% in the Exome
Sequencing Project, 1000 Genomes or ExAC Browser databases, and if they appeared in
the dbSNP137 common database. Pathogenicity predictions were made using the online
prediction software programs SIFT, PolyPhen (Flanagan et al., 2010) and MutationTaster
(Schwarz et al., 2014). The GEMINI program was also utilized for variant analysis (Paila
et al., 2013)
2.2.6.3 Illumina

Illumina whole exome sequencing (exome capture kit SureSelectXT V5+UTR;
TheragenEtex, Korea) was performed on 2 affected family members (D4 and D8). All
exomes were >90% covered to >20-fold. The file processing from FASTQ to VCF was
performed

as

per

the

GATK

best

practices

guidelines

version

3.6

(https://software.broadinstitute.org/gatk). Variant annotation was performed with in37

house scripts using the ANNOVAR and GEMINI software programs, as per the Ion Proton
section described above.
2.2.7 Linkage analysis
Variants were extracted from the Ion Proton whole exome sequencing data using the
vcf2linkdatagen.pl script from LINKDATAGEN (Bahlo & Bromhead, 2009) to infer
genotypes at the location of HapMap Phase II SNPs (https://www.ncbi.nlm.nih.gov /pmc/
articles/ PMC2689609/). This allows linkage analysis to be performed without requiring
genotyping arrays. Mendelian inheritance errors were identified and removed. MERLIN
(Abecasis et al., 2002) was used to perform parametric multipoint linkage analysis, using
a fully penetrant dominant disease model. Linkage calculations were performed using an
assumed disease allele frequency of 0.0001.
2.2.8 Variant confirmation and prioritization
Variants identified were prioritized according to likely functional relevance to
Dupuytren’s pathology and the predicted pathogenicity of the variants. Pathogenicity of
single nucleotide variants was estimated by the use of the SIFT, PolyPhen2 and Mutation
Taster tools (Adzhubei et al., 2010; Schwarz et al., 2010; Sherry et al., 2001). For selected
variants PCR and Sanger sequencing confirmation of the presence/absence of the variant
in affected/unaffected family members was used.

2.3 Results
2.3.1 Genes identified using the SOLiD platform

The initial experiment involved WES of 3 affected family members using the SOLiD
platform. This process identified four hundred variants common to all three family
members sequenced. This number was significantly reduced by selecting only those that
were both non-synonymous (therefore more likely to be disease causing) and
heterozygous (given the autosomal dominant nature of inheritance). Also by using two
custom variant-filtering steps: (1) one against the 1000 Genomes database (February 2012
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release) and eliminating any variants detected in >1% of the population, and (2) one
against the dbSNP135 common database and again eliminating any common SNPs
identified. This resulted in a final list of 43 identified genes containing non-synonymous
heterozygous mutations (Table 2.1).

For further family member sequencing a subset of this total (9 candidates) was selected.
The list was refined by using biological databases to identify those genes with the most
likely relevance to what is known of Dupuytren’s pathology (for example search terms
included collagen deposition/secretion; skin; male hormones; diabetes). Databases
(including ENSEMBL and Genecards) were both used to investigate gene function. In
addition each mutation was assessed for likely deleterious impact using in silico predictive
tools. A list of nine candidate genes was ultimately selected using this approach (Table
2.2).
Table 2.1: list of candidate genes from WES analysis. Final candidate gene list with all genes containing a nonsynonymous heterozygous variant as outlined in the methods section.These genes were identified by comparative
analysis of only affected family member DNA samples.

All 43 genes contain a non-synonymous variant and are heterozygous in the family
members analysed by WES
GENE NAME

GENE NAME

GENE NAME

GENE NAME

ADAM15

FAM1882

PLXNA2

WDR64

AGPAT5

GBA3

POLR3A

ZFYVE27

AKAP8

HSD3B1

PTPRD

PKD1L3

ANKRD31

ICAM1

RNF169

EXOC6B

BORA

JHDM1D

S100A7L2

VPS41

C1orf204

KCNV2

SERPINA1

PDCD11

CCDC80

KLF11

SPHK1

EMR4P

CDRT4

KRT24

TUFT1

VPS37A

CNTN5

MED1

uc021qtm

OR4C3

COBL

MX2

VAV1

DNR

CYP2F1

NDUFS2

VPS13A
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Table 2.2: Selected mutations for intial SNP analysis
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2.3.1.2 PCR fragment sequencing in additional family members

Sanger sequencing was then conducted on short fragments containing each gene mutation
in additional family members. Heterozygous mutations were identified by the presence of
two alternate reads at the single nucleotide position (Figure 2.2A). Non-affected and
affected family members were sequenced.

None of the identified mutations segregated with the affected members of the family
(Table 2.3). All mutations were not present in at least 2 affected family members, except
for the ADAM15 gene mutation that was only not present in one affected family member
(Table 2.3).

Figure 2.2: Sanger sequencing in family members for heterozygous non-synonymous variants in selected genes.
Heterozygous nucleotides are identified by the presence of two peaks at the individual sequencing site being investigated
(A), compared to the single peak observed for homozygous nucleotides (B). Arrow indicates nucleotide position of
interest.

No variants segregated in all affected family members (Y is a positive sample containing
heterozygous variants, and N is a sample not containing the heterozygous variant).
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Table 2.3: Sanger sequencing of putative causative variants in additional affected and non-affected family members

No identified genes contained the SNP of interest in all affected patients tested and mutations were
identified in family members that continue to be unaffected at the time of the study making them unlikely
candidates.

Prior to assessing other candidate variants in the family an additional clinical visit was
made to confirm diagnosis of those family members that were affected. During this
revisiting process a family member was identified that had been incorrectly classified as
an affected family member when there was no evidence of the disease at the follow-up
visit. Therefore additional WES was then conducted on 2 other family members that were
identified as affected during the clinical visits.
2.3.2 Genes identified using the Ion Proton sequencing platform
The misdiagnosed exome sequence was removed from analysis and the identification
process was repeated, this time using the Ion Proton sequencing platform. This resulted in
a list of 28 variants being identified that were common to all four affected exomes
sequenced (Table 2.4). All four affected family members sequenced for this analysis were
positive for Dupuytren’s disease at the follow-up clinical visit.
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Table 2.4: Variants identified in 4 family members by WES
List of 28 variants identified by WES of four affected family members with Dupuytren’s disease (all variants were
heterozygous and present at <0.1% in the ExAC database). Table shows Chromosomal location, reference and actual
base at this position, gene name, type of mutation and the % present in the ExAC database.

Chr Start

Ref

Alt

Gene

Mutation

ExAC

1

228596057

C

T

TRIM17

non-synonymous SNV

0.0002

10

135368906

G

C

SYCE1

synonymous SNV

0.0041

13

52693478

A

G

NEK5

nonsynonymous SNV

0.0001

13

46562926

C

T

ZC3H13

synonymous SNV

0.0089

15

63014680

G

A

TLN2

synonymous SNV

0.0032

17

8167600

TG

GC PFAS

non-frameshift

absent

substitution
17

4462264

G

A

GGT6

synonymous SNV

0.006

18

47778134

C

T

CFAP53

non-synonymous SNV

0.0024

22

19750797

C

T

TBX1

synonymous SNV

0.003

3

169485336

A

G

ACTRT3

non-synonymous SNV

0.0033

3

130107567

T

G

COL6A5

non-synonymous SNV

0.0034

3

52383001

G

A

DNAH1

non-synonymous SNV

0.0049

3

38565782

C

T

EXOG

non-synonymous SNV

0.0019

3

39145040

T

C

GORASP1

non-synonymous SNV

5.04E-05

3

52836533

G

A

ITIH3

non-synonymous SNV

0.0087

3

129150385

C

G

MBD4

non-synonymous SNV

0.0054

3

140401440

C

T

TRIM42

non-synonymous SNV

0.0009

3

165547451

C

T

BCHE

synonymous SNV

3

169555275

A

G

LRRIQ4

synonymous SNV

0.0045

3

52507794

G

A

NISCH

synonymous SNV

0.0052

3

51458183

G

A

VPRBP

synonymous SNV

0.0074

4

73935320

A

G

COX18

non-synonymous SNV

0.0052

6

31238909

GT

AG HLA-C

non-frameshift

Absent

substitution
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7

24910408

T

C

OSBPL3

synonymous SNV

0.0051

9

136419629

G

A

ADAMTSL2

non-synonymous SNV

Absent

9

130472886

A

G

CFAP157

non-synonymous SNV

0.0002

9

130265116

C

T

LRSAM1

non-synonymous SNV

0.0001

9

126213026

T

C

DENND1A

synonymous SNV

0.0007

2.3.2.1 Linkage analysis

Of these 28 variants identified, 17 were non-synonymous (Table 2.4). In addition to the
identification of variants of interest, linkage analysis was also used to screen for regions
of positive linkage and also to screen those regions that were definitely not linked to the
disease (Table 2.5. Fig. 2.3).
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CHR

POS

LABEL

LOD

ALPHA HLOD

Table 2.5: Linkage analysis to
eliminate candidate genes.

3

0.5876 rs969818

0.9017

1

0.9017

3

0.5957 rs7634545

0.9019

1

0.9019

3

0.5974 rs3796187

0.9019

1

0.9019

3

0.601 rs4234259

0.902

1

0.902

3

0.6044 rs1118148

0.9021

1

0.9021

3

0.6071 rs6809649

0.9022

1

0.9022

3

0.6105 rs2070488

0.9022

1

0.9022

3

0.6122 rs1805124

0.9023

1

0.9023

3

0.6156 rs6599250

0.9023

1

0.9023

3

0.6209 rs2270770

0.9025

1

0.9025

3

0.6272 rs1714414

0.903

1

0.903

3

0.6387 rs1716979

0.9009

1

0.9009

candidate genes due to

3

0.6405 rs3733053

0.9006

1

0.9006

their

3

0.6459 rs40416

0.899

1

0.899

negative regions (Table

3

0.6489 rs2240859

0.8972

1

0.8972

2.5, Figure, 2.3). The

3

0.653 rs3772165

0.8921

1

0.8921

remaining list contained

3

0.6622 rs4682960

-0.1603

0

0

14

3

0.6641 rs2037358

-0.2649

0

0

genes. Of these, only

3

0.6716 rs2248991

-3.398

0

0

3

0.6732 rs2742399

-3.3786

0

0

-3.398

0

0

3

0.677 rs11130097

3

0.6798 rs4082155

-3.2509

0

0

3

0.6822 rs1062633

-3.0446

0

0

3

0.6867 rs352166

-3.0897

0

0

3

0.6895 rs2230493

-3.1819

0

0

3

0.691 rs6805302

-3.3981

0

0

3

0.6939 rs2250736

-3.3365

0

0

3

0.6973 rs4687757

-3.398

0

0

3

0.7098 rs6782115

-3.3467

0

0

Only 14 potential candidate
genes remain after screening

Regions

could

be

elimitated using linkage
scores

across

this

chromosome, leading to
the removal of VPRBP,
DNAH1,
ITIH3

NISCH
as

potential

location

potential

EXOG

and

and

within

candidate

GORASP1

were within regions with
positive linkage scores
(Table 2.6).

The LOD score was calculated for individual SNPs across a region of chromosome 3.
SNPs were assessed for positive (green), neutral (yellow) or negative (pink) LOD scores.
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Figure 2.3: Linkage analysis of individual chromosomes.

Linkage analysis identifies positive and negative regions in WES of 4 affected family members. a/b show
regions across Chromosome 3, which could then be used to eliminate candidate genes within the negative
regions, including VBPRBP and DNAH1.
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Table 2.6: Non-synonymous variants remaining after removal of those with a negative linkage score

Genes highlighted in bold are those with a positive linkage score, other genes not in bold were not
excluded by linkage analysis.

Chr

Start

Ref Alt Gene

1 228596057 C

Mutation

ExAC

T

TRIM17

non-synonymous SNV

0.0002

13

52693478 A

G

NEK5

non-synonymous SNV

0.0001

18

47778134 C

T

CFAP53

non-synonymous SNV

0.0024

3 169485336 A

G

ACTRT3

non-synonymous SNV

0.0033

3 130107567 T

G

COL6A5

non-synonymous SNV

0.0034

3

38565782 C

T

EXOG

non-synonymous SNV

0.0019

3

39145040 T

C

GORASP1

non-synonymous SNV

5.04E-05

3 129150385 C

G

MBD4

non-synonymous SNV

0.0054

3 140401440 C

T

TRIM42

non-synonymous SNV

0.0009

4

73935320 A

G

COX18

non-synonymous SNV

0.0052

9 130472886 A

G

CFAP157

non-synonymous SNV

0.0002

9 130265116 C

T

LRSAM1

non-synonymous SNV

0.0001

12 genes were identified after refinement by linkage analysis, and only two were in regions
of positive linkage (shown in bold).
2.3.2.2 In silico prediction

Using in silico prediction, the likelihood of each mutation being deleterious was assessed
(Table 2.7). None of the 12 variants were predicted to be deleterious by all in silico
analyses. The gene with the highest predicted value for being deleterious, and predicted
to have a high impact on protein function, was COL6A5. Given the well-established
importance of other collagen types in fibrosis, this gene was therefore investigated further.
In addition, given that both GORASP1 and EXOG were also predicted to be potentially
deleterious and were found in regions of positive linkage, these variants were also
investigated further.
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Table 2.7 In silico prediction of the likelihood of non-synonymous variants being deleterious to function.

Use of in silico predictive tools to identify deleterious mutations and prioritise further analysis showed
consensus across three different in silico platforms (SIFT, Polyphen and Mutationtaster) that the genes in a
region of positive linkage contained mutations likely to be deleterious (D =deleterious, B or N benign or
non-deleterious mutations; L and M suggest Low/Medium impact of the mutation)

COL6A5 has the highest level of prediction to be deleterious across all predictive
programs, and the variant was also predicted to have a high impact on protein function by
Mutation Assessor scoring (Predicted types of mutation; T - tolerated, B - benign, D deleterious; Impact of mutation predicted by Mutation Assessor as; L – low, M - medium,
H – high).
2.3.2.3 Sequencing of COL6A5, GORASP1 and EXOG fragments in family members

To investigate whether these variants segregated within the family with Dupuytren’s
disease, Sanger sequencing of PCR fragments was conducted using multiple family
samples. Sequencing was focused on 3 candidate genes. GORASP1 and EXOG were both
selected due to their identification in a region of positive linkage from initial analysis. In
addition COL6A5 was selected for sequencing due to the fundamental link between
collagen deposition and fibrotic disease. Initial sequencing showed that no variant
segregated with the disease in additional family members (Fig. 2.4). Interestingly, no
family member tested appeared to have a COL6A5 variant present (Fig. 2.4). Given the
large number of siblings within the family being tested it was unusual to observe no
heterozygotes in the PCR analysis. Investigation of the sequence underlying the original
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primers used for PCR demonstrated the presence of additional SNPs that may have
disrupted the amplification ability, leading to detection of only the wildtype allele.
Therefore additional primers were designed and COL6A5 was again sequenced. However,
COL6A5, whilst positive for the variant in some family members, did not segregate with
the disease in all family members tested, suggesting this variant is not disease-causating
in the family being investigated (data not shown).

Figure 2.4: Sanger sequencing of candidate gene fragments in additional family members.Sequencing of
COL6A5 (A), GORASP1 (B) and EXOG (C) fragments in additional family members. No mutation appears
positive in all disease positive family members tested. COL6A5 appears to have no heterozygotes present
when tested with this primer set.
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2.3.4 Genes identified using the Illumina platform
Illumina WES (exome capture kit SureSelectXT V5+UTR; TheragenEtex, Korea) was
performed on DNA from two affected family members (D4 and D8). The variants
identified using this platform included twelve new candidates (Table 2.8) in addition to
those previously found by the use of SOLiD and Ion Proton sequencing platforms. Of the
twelve novel variants identified using the new platform, none had been previously
identified using other platforms, even if restricting the comparative sequencing to the two
members sequenced using the Illumina platform (D4 and D8 only). Of the new genes five
have previously been recorded in association with clinical conditions exhibiting
inflammatory changes and immune reactions. No further investigation of these genes was
undertaken at this point as a novel approach to triangulate alternative data sources was
undertaken to further investigate the mutations underpinning Dupuytren’s disease.
Table 2.8: Additional genes identified that contained non-synonymous variants in family members sequenced using
the Illumina WES platform.

Gene

Gene

Gene

Name

Name

Name

CYP2T3P

IRGC

PIK3R4

TCP11X3P

TRIM21

HSPA12B

MEX3D

PSG8

TOLLIP

VNN3

Gene Name

Gene Name

ALPI
ANKRD36BP

Gene Name

The use of an alternative sequencing platform highlights new variants of interest,
demonstrating the differences arising from the platform used. A number of these genes
are related to inflammatory diseases, suggesting a possible role in Dupuytren’s disease.

2.3.5 Summary
WES of family members with diagnosed Dupuytren’s disease was used to investigate the
presence of non-synonymous variants within the family that may be causative. Using three
alternative sequencing platforms with subsequent PCR sequencing for mutations in the
wider family, no individual variant was found to segregate with the disease in this family.
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2.4 Discussion
2.4.1 Non-synonymous variants identified by WES in a family with Dupuytren’s
disease
The data from the WES analysis of four related, affected individuals using the Ion Torrent
platform identified non-synonymous heterozygous variants in 12 candidate genes that also
conformed to the selection criteria. The three candidate genes that either showed positive
linkage (GORASP, EXOG) or were known to have a strong likely functional link to
fibrosis (COL6A5) were all subsequently tested using PCR for segregation within the
family. None of the variants tested was shown to segregate with all affected members of
the family, thereby ruling out these variants as being disease-causing. Therefore other
variants identified should be followed up for this study.

COL6A5 was indicated as a strong possible candidate gene from the lists of genes
containing non-synonymous variants due to the well-known important role of collagen in
fibrosis (Wynn Ta, 2008). The COL6A1 subunit has previously been shown to be elevated
in expression in Dupuytren’s tissue (Shih et al, 2009) and therefore other subunits of
COL6 are potentially strong candidates. Collagen VI is a component of the extracellular
matrix of almost all connective tissues, including cartilage, bone, tendon, muscles and
cornea, where it forms abundant and structurally unique microfibrils organized into
different suprastructural assemblies. The precise role of collagen VI is not clearly defined
although it is most abundant in the interstitial matrix of tissues and often found in close
association with basement membranes (Fitzgerald et al 2013).
A recent paper reviewing ‘Collagen Type VI-Related Disorders’ (Lampe, Flanigan, et al;
2004; 2012) discusses the clinical characteristics of several disorders that represent a
continuum of overlapping phenotypes. These include Bethlem myopathy and Ullrich
congenital muscular dystrophy (CMD) and two rare, less well-defined disorders,
specifically autosomal dominant limb girdle muscular dystrophy and autosomal
recessive myosclerosis myopathy. These phenotypes however share little overlap with
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Dupuytren’s disease, and the subsequent findings that family members positive for the
disease did not all share the mutation identified by WES suggest that this variant is
unlikely to be causative for Dupuytren’s in this family.

However, it is important to consider that the lack of segregation does not necessarily
preclude the variants from being important in the pathology of Dupuytren’s disease. It is
possible, for example, that an individual member of the family could be positive for
Dupuytren’s disease due to a somatic rather than an inherited mutation, particularly since
Dupuytren’s disease is a relatively common disease. This would effectively mask the
disease-causing mutation in most family members by providing a positive phenotype
without the inherited mutation. It is also possible due to incomplete penetrance that there
are members of the family who are ‘carriers’ of the causative mutation(s) but do not
express the Dupuytren’s disease phenotype due to different environmental influences.
Therefore, it is important to consider the genes identified as containing rare variants for
potential functional relevance to the pathophysiology of Dupuytren’s disease.

The first list of potential candidates needed to be discarded due to errors in diagnosing
family members, highlighting the importance of clinical diagnoses in genetic studies.
Fortunately, the individual WES data for each person was still accurate and new
comparative analyses could be performed based on the revised clinical diagnosis of the
family member in question.
Subsequent to the Ion Proton sequencing used for 4 family members the additional
Illumina sequencing of two affected individuals provided a list of a further 12 candidate
genes with non-synonymous rare variants. These 24 potential candidate genes will need
to be further investigated, with the focus initially on the 21 genes not yet investigated.
Interestingly, the genes containing variants that may be associated with the disease appear
to comprise subsets of genes with similar roles/functions. This may indicate the
importance of certain processes in the pathogenesis of Dupuytren’s disease in this family.

Many of the genes containing non-synonymous variants have functions related to
angiogenesis, immune responses and neural functions. Many of these processes have
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important and well-established roles in wound healing and fibrosis, suggesting that the
genes with non-synonymous variants may be good candidates for futher investigation.
Indeed, whilst it is clear that fibroblasts play an important role in fibrotic disease, it has
also been suggested that rather than fibroblast dysfunction being the driver of fibrosis, it
is external triggers of fibroblast collagen production that are altered (Fig. 2.5). As outlined
in Figure 2.5, it has been shown that external signals impact significantly on fibroblast
function and fibrosis. For example, keratinocytes have been shown to be important in
keloid disease, whereby it is the epithelial cells that appear to drive the disease rather than
changes to the fibroblasts. Similarly, immune drivers of fibrosis such as in sclerosis also
occur external to the key collagen producing fibroblasts. Therefore, it is possible that the
mutations that underpin Dupuytren’s disease exist in the current shortlist of candidate
genes and influence the disease through an indirect influence on fibroblast activity. The
possible role for these genes that have not been tested and the evidence for their likely
involvement in Dupuytren’s pathogenesis are discussed in more detail below.

Figure 2.5: Factors influencing fibroblast differentiation and function.

Diagram illustrating the potential role for other physiological processes to influence
fibroblast function and ultimately fibrosis in Dupuytren’s disease.

53

2.4.2 Genes involved in angiogenesis
The HSPA12B gene has an important role in endothelial cells and in angiogenesis
(Steagall et al., 2006). Angiogenesis is an important process in tissue damage repair and
has been implicated in fibrosis, although the role of angiogenesis remains controversial
(Hanumegowda et al., 2012). It has been postulated that increased angiogenesis plays an
important role in progressive fibrosis such as keloid scar formation (Zhang et al., 2015),
but equally there is evidence that a lack of angiogenesis can induce hypoxia and a fibrotic
response in damaged tissue (Lokmic et al., 2012). Despite the unclear role for
angiogenesis in contributing to fibrotic disease, it is possible that this process is important
in the progression or initiation of fibrosis. HSPA12B has also recently been shown to be
protective against cardiac damage in a model of myocardial infarction (Li et al, 2013). In
this study HSPA12B attenuated tissue damage through promotion of more rapid
vascularization of damaged tisse and therefore faster repair. Therefore it could be
hypothesized that a mutation in this gene could lead to increased or decreased
vascularization, dependent on the mutation type, in response to the damage to tissue
caused by extensive use of the hands over many years. A link between Dupuytren’s
disease and vascular supply has previously been hypothesized due to the correlation
between type II DM and the incidence of Dupuytren’s disease. Therefore HSPA12B
remains a candidate gene for further investigation.
2.4.3 Genes with roles in inflammatory processes
Studies of genetic variants associated with susceptibility and mortality of idiopathic
pulmonary fibrosis (IPF) have identified several rare mutations and one common SNP of
MUC5B (Noth et al, 2013). Through a large international consortium and a genome-wide
association study variants associated with the TOLLIP and SPPL2C genes were also found
to be associated with IPF susceptibility. These associations and the reduced expression of
TOLLIP in patients with IPF who carry TOLLIP SNPs emphasise the potential importance
of this gene in IPF. The TOLLIP mutation identified by the Illumina platform in the
affected Dupuytren disease family members has previously been reported in
lymphoproliferative syndrome and inflammatory signaling (Cohen, 2014). Therefore
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given the role of TOLLIP in IPF and its importance to immune function it is also a strong
potential candidate gene for Dupuytren’s disease.

The genes IRGC, TRIM21 and VNN3 are all commonly highly expressed in a number of
inflammatory and immune-related disorders. VNN3 is one of two members of the vanin
gene family found to be induced at the mRNA and protein level by psoriasis-associated
pro-inflammatory cytokines (Jansen et al., 2009), whilst TRIM21 has been investigated
both for its role in physiological and pathological immunity (Yoshimi, 2012; McEwan,
2016). TRIM21 has been shown to be protective against aberrant protein accumulation in
a model of Alzheimer’s disease, whilst TRIM21 is also known to have potent anti-viral
effects. Given the diversity of roles for these genes and their importance to immune
function it is reasonable to expect that significant mutations in these genes would lead to
a more widespread phenotype than observed. Nevertheless there is evidence that the
immune system may be an important contributor to the initiation of Dupuytren’s disease
and these genes require further investigation.
2.4.4 Candidate genes with neural functions
The third ‘cluster’ identified appear to be genes associated with neural function. Whilst to
date there is little evidence for a role of peripheral nerves in the development of
Dupuytren’s disease, cutaneous innervation is well known to be important for wound
healing and some recent evidence exists for a role in hypertrophic scar formation (Li,
2015; Lavardet, 2015; Roosterman, 2006; Cheret, 2013). Therefore it is important to
assess mutations in genes with important roles in peripheral nerves as these may play an
as yet unidentified role in Dupuytren’s pathology. The LRSAM1 gene identified in this
study has previously been associated with Charcot Marie Tooth (CMT) syndrome. This
disorder begins with atrophy and weakness of distal muscles in the leg (e.g. peroneal),
advancing insidiously to involve other muscles of the leg and arm. The hereditary
polyneuropathy affects both sensory and motor pathways with disparate clinical
presentations.
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Peripheral neuropathy is a clinically variable and genetically heterogeneous disease. In a
cohort of patients Gonzaga-Jauregui et al. identiﬁed causative variants in 45% of the
families studied, proposed candidate disease genes for an additional three families, and
recognized a signiﬁcant variant burden in patients versus controls that likely contributes
to phenotypic variability (Gonzaga-Jauregui et al., 2015). Whilst Dupuytren’s patients do
not present with peripheral neuropathy, other peripheral nerve dysfunction may be
important. For example the role that peripheral nerves can play in inflammation and the
immune response may be important, similar to the studies to date suggesting immune
dysfunction is central to the disease. However, at present with the limited evidence for an
impact of innervation on Dupuytren’s disease candidate genes with functions relevant to
peripheral nerves should be prioritized lower than those involved in other processes with
stronger evidence such as the immune and vascular response.

2.4.5 The absence of genes identified in previous studies
The only known genome-wide analysis from members of one family of Dupuytren’s
affecteds is the extensive investigation of a five generation Swedish family with autosomal
dominant inheritance of the disease, reported by Hu et al. (2005). These investigators
established linkage to a single 6cM region between markers D16S49 and D16S3032 on
Chromosome 16q. There is no evidence from the current study to confirm this finding
with no mutations observed in genes within this region.
Similarly the GWAS of 960 unrelated Dutch persons with the Dupuytren’s phenotype
yielded an association with 11 SNPs from 9 different loci, six of which contain genes
known to be involved in the Wnt-signalling pathway ie WNT4, SFRP4, WNT2, RSP02,
SULF1 and WNT7B. No mutations were found in any of these genes in the current
investigation.
Meanwhile, several studies of gene expression analysis in Dupuytren’s disease, based on
cord tissue samples from affected hands, have identified a larger number of genes with
dysregulated expression levels in Dupuytren’s tissue (Zhang et al., 2008; Forrester et al.,
2013). However no mutations in the genes with the most significant differences in
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expression in these studies (for example in top 50 upregulated and down-regulated in
Forrester et al) were found in this family.

As with many conditions where there is phenotypic variance, in this case related to age of
onset, palmar involvement, degree of digital contractures, rate of progression of
fibromatosis and racial differences, there is reason to consider multiple gene involvement
and that it is changes to similar pathways that likely underlie the disease rather than
common specific mutations in an individual gene or genes. It is also important to consider
with the expression studies that the genes identified as being most dysregulated may not
be related to the cause of the disease but rather their dysregulation may be a consequence
of the disease, thus explaining the disparity between genetic studies and expression studies
of this disease. Given the importance of environmental factors, the use of different
populations in these studies compared to the West Australian family in this current study
and the different approaches used it is not surprising that overlap has not been observed.
However, WNT signaling has been extensively implicated in Dupuytren’s disease, and
the absence of any genes with known critical functions in WNT signaling in this study is
surprising. This may be due to the limitations of this study approach and the restrictions
used in identifying mutations of interest (see section 2.4.7).
2.4.6 The advantages of using WES to identify causative mutations
One of the advantages of using a genetic approach is that it is potentially feasible to
identify the trigger for Dupuytren’s disease. This is in contrast to a second common
approach that uses diseased tissue as the source material for identifying transcriptome or
proteomic changes related to Dupuytren’s disease. Because the use of diseased tissue
invariably involves cells that have been cultured or isolated it is very difficult to identify
causative changes as opposed to consequential changes. This is particularly true in
diseases that are generally treated surgically at quite a late stage such as Dupuytren’s
disease, where the time between disease initiation and obtaining tissue is substantial.
During this period it is likely cells undergo many changes in phenotype and expression
and therefore identifying the causative changes is a significant challenge.
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The essential benefit of WES is its selective focus on the part of the genome encoding for
proteins to identify non-synonymous mutations that are likely to affect protein function
and therefore underlie disease. While only functional mutations (rather than those
affecting expression levels, for example within promoter regions) can be identified, it
reduces significantly the number of data points identified and therefore is more likely to
be able to find disease-causing mutations. WES is restricted to mutations that change the
coding sequence (although they can be synonymous) and therefore whilst this restricts the
number of data points it also provides an opportunity to identify functional mutations in
smaller populations such as the family investigated here.
Although Dupuytren’s disease can be sporadic, even within a pedigree exhibiting familial
inheritance, use of the WES approach in a family cohort offers a strong likelihood of
identifying the same disease-causing mutations in all affected samples – and similar
phenotype of disease within the family would suggest a common cause. Compared with
the GWAS type approach exome sequencing also provides a list of mutations with likely
functional impact, rather than mapping results that link to likely regions of interest. This
therefore provides a better opportunity for further functional investigation of the impact
of the mutations and to demonstrate a functional link to the disease.

WES provides the possibility of locating rare functional changes within the protein-coding
part of the genome (the exome) as using family members means the shared DNA is
extensive and they will have the same causative mutation – whilst the exact mutation
identified through WES in a family cohort may not apply to all affecteds the gene and/or
pathway will be common to others and can therefore assist in better understanding the
disease. The GWAS approach can only find common regions across large populations,
and is not suitable to locate rare functional mutations.
2.4.7 Limitations of using the WES approach
The use of WES as a strategy to identify disease-causing mutations has been successful in
many diseases and continues to be a mainstay of disease SNP identification strategies
[Biesecker et al., 2011]. However, as with all strategies currently employed there are
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limitations to this approach that can lead to misidentification or non-identification of
mutations linked to disease (Sims et al., 2014). Less than 2% of the human genome
contains protein-coding sequences and these regions must undergo exon-targeting capture
process before being sequenced to identify clinically relevant alleles. It is important also
to determine the coverage of these captured regions – i.e. depth of sequencing – as the
higher the coverage the more likely the captured base will be accurate and not a false read
due to technical error (Li et al., 2015). Inadequate coverage of certain exomes/genes could
lead to false negatives and the omission of important variants. Equally, inadequate
coverage can lead to false positive variant identification. As the goal of WES is to identify
those mutations that may be potentially pathogenic it is important to have efficient
strategies and appropriate variant analysis pipelines. Depending on filtering parameters
applied it is possible for a pathogenic variant to be missed if it is not targeted for analysis.
Targeted sequencing has the advantage of increased sequence coverage of regions of
interest at lower cost and higher throughput compared with random sequencing methods.

Genome sequencing could avoid some of the technical challenges faced by WES but it
remains expensive and requires more sophisticated analysis pipelines to filter and identify
the increased number of potential variants. Indeed, it is unlikely that whole genome
sequencing would provide suitable candidate lists for further investigation in a small
family centric study such as that conducted here. However, filtering much larger datasets
from small family studies such as that becomes increasingly difficult, and the relatively
limited knowledge of the function of all non-coding bases in the DNA increases the
complexity of identifying changes of interest when using whole genome sequencing.
Genetic variants identiﬁed using WES induce a phenotype that can vary between
individuals in penetrance or physiological effect and may depend on (1) environmental
factors; (2) modiﬁer genes and/or the epigenome; and (3) the additive/synergistic effect
from another genetic variant (digenic inheritance) (Majewski et al., 2011). Highpenetrance variants induce a strong physiological effect and these alleles have usually
been identiﬁed as causative for Mendelian monogenic disorders using linkage studies in
families. Low penetrance variants have a weak phenotype and causative alleles are
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typically identiﬁed in large case/ control cohorts as part of the study of complex trait
disorders. Common high-penetrance disease variants are rare as they would normally be
eliminated from breeding populations, except in cases of balancing selection where
heterozygotes have an advantage over homozygotes (e.g. sickle cell disease). The
distinction between monogenic and complex diseases is therefore operational as all
genetic variants are de-facto transmitted in a Mendelian fashion and thus amenable to
discovery using WES, giving this technique far wider applicability than simply the study
of rare monogenic disorders (Rabbani et al, 2014).

By limiting the further investigation to those mutations known to occur in <1% of the
general population the majority of those considered unlikely to be involved with
Dupuytren’s disease have been excluded. It remains possible, however, particularly in
light of subsequent findings, that one or more relevant mutations may have been excluded
by this means.

Since all of the first generation of affected family members had only one parent known to
have Dupuytren’s disease, the mutation must be heterozygous in these patients and results
in the familial pattern of autosomal dominance observed in the family pedigree.
Significantly, only one previous study has proposed an autosomal recessive model for
inheritance of Dupuytren’s disease (Bayat et al., 2003) based on a statistical analysis of
transforming growth factor  receptor (TGFR) gene polymorphisms obtained from DNA
sequencing of peripheral blood samples. Their conclusion, however, based upon
investigation of a small range of candidate susceptibility genes before it was possible to
detect candidate gene loci, was that Dupuytren’s disease “appears to be a complex
oligogenic rather than a monogenic condition that segregates into multiple modes of
inheritance” (see also Burge, 1999). The pedigrees of other families with Dupuytren’s
reported in the literature strongly support an autosomal dominant pattern of inheritance
(Gudmundsson et al., 2000). Synonymous mutations, almost by definition, will not
usually affect translation of otherwise normal amino acid sequences to abnormal protein,
but the possibility of interaction between multi-purpose codons (DUONS) causing
interference with normal processing during transcription and/or translation must be
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considered (Stergachis, 2013). The study reporting the existence of codons with dual
function may provide a mechanism by which synonymous variants may be more important
in disease, and suggests that the strategy employed in this chapter of only investigating
non-synonymous mutations is limited (Weatheritt, 2013).
There is indeed evidence to suggest that changes in a gene’s sequence that are silent with
respect to protein sequence are not always silent with respect to function (Gingold &
Pilpel, 2011). From their assessment of mutations obtained from large-scale sequencing
of cancer genomes the authors of a recent review article have concluded that synonymous
mutations within oncogenes represent 6-8 percent of all driver mutations due to single
nucleotide changes, and that approximately half of synonymous drivers alter splicing,
which in turn may influence cancer progression (Supek et al., 2014) Of further relevance
is the fact that synonymous mutations can also alter protein folding, thereby contributing
to tumour progression (Kimchi-Sarfaty et al., 2007; Zhang et al., 2009; Zhou et al., 2013).

Selection of priority genes of interest was based on either gene function being known to
be relevant to Dupuytren’s pathology (for example ADAM15, KLF11); genes known to be
involved or expressed in relevant cell types (for example CDCC80 expression in
fibroblasts); genes that had been linked to conditions also linked by epidemiology to
Dupuytren’s disease (for example JHDM1D) and genes that had previously been
identified or were similar to those identified in other studies of Dupuytren’s disease (for
example ADAM15). This selective process creates the potential for the elimination of other
mutations that may be critical, but is necessary to restrict further investigation to a list that
can be interrogated more fully. Nevertheless it is an important limitation that may lead to
the omission of important mutations in this study.

2.5 Summary
Within the family members currently investigated a limited number of mutations
potentially relevant to Dupuytren’s disease have been identified. However no overlap with
the studies of others was identified and no mutations that were sequenced in other family
members appeared to segregate with the disease phenotype. Therefore it has not been
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possible at this stage to identify a causative mutation. The limitations of this approach
include the use of WES that will exclude non-coding mutations as well as the assumptions
made to restrict the number of mutations identified in the small number of exomes
sequenced. Therefore additional approaches may facilitate a better understanding of the
causes of Dupuytren’s disease in the Western Australian population. To follow-up this
family based study the next chapter will focus on a population approach, using data
derived from a community-based health survey in which people were identified as having
Dupuytren’s disease. The aim of this study will be to then interrogate potential regions of
the genome for overlap with the family study presented in this chapter to determine if a
causative gene/mutation can be identified through the combination of these different
approaches.
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CHAPTER 3
Aim. 2 To investigate the presence of identified mutations in a wider population-based
cohort of people with Dupuytren’s disease.
3.1 Introduction
Genome Wide Association Studies (GWAS) use a high-density map of SNPs across the
entire genome to localize regions of interest with respect to disease. The relative
occurrence of specific SNPs in affected and unaffected populations is identified and
compared to locate regions of the genome that are in high linkage disequilibrium. That is
the region strongly associated with the presence of the disease. These studies require large
populations of both affected and unaffected individuals to be effective in isolation.
3.1.1 The Busselton Population Health Survey
Repeated cross-sectional health surveys of adults living within the south west coastal
community of Busselton have been carried out from 1966 to 2009, although there have
been only two major surveys since 1990, in 1994-95 and 2005-06. Busselton has a
relatively stable population of predominantly European descent and participation rates
ranged between 64 to 91 percent of eligible adults. Randomised participation was by
invitation based on the electoral rolls with recruitment via letter of introduction and
subsequent personal interview. The population recruited is approximately 5000
individuals, although not all individuals were assessed for all conditions in all surveys so
not all subsequent studies have been able to use the entire population.

An essential element of the Busselton study has been the longitudinal follow-up of the
same cohort at intervals of three to five years (Phase II)(eg Busselton Healthy Ageing
Study, 2010; James et al, 2013). The elements of each periodic community survey have
included a limited clinical examination, focusing on certain medical conditions which
occur commonly and which are most likely related to lifestyle, and a comprehensive
questionnaire in support of the long-term clinical progress through childhood and all
stages of adulthood. In the 1994-95 survey, at the request of Dr Pearce, two additional
63

questions pertaining to the participant’s Dupuytren status (affected or unaffected) were
included in the surveys. All adults included in the survey also submitted to examination
of their hands for evidence of the clinical manifestations of Dupuytren’s disease. Those
responsible for examining the hands were not trained or medically qualified and the results
suggest a high degree of inaccuracy, thereby precluding further interpretation or analysis.
The questions specific to Dupuytren’s disease were:
1. Have you observed the appearance of palpable bands or cords in the palms or digits?
2. Have you had surgery for Dupuytren’s disease affecting your hands?

Whereas over four hundred individuals claimed to have palpable palmar bands or cords,
suggesting a possible Dupuytren’s phenotype based on subjective self-examination, only
forty-eight admitted to having surgery for a confirmed clinical diagnosis of Dupuytren’s
disease. The veracity and therefore reliability of the former result must be questioned as
it included all age groups, which suggests an incidence of Dupuytren’s disease that is not
only highly improbable but virtually impossible. It would be difficult to relate this group
to a cohort with a diagnosis of Dupuytren’s disease with any confidence. As their DNA
has been made available, however, an analysis of association may be made with some
comparisons with GWAS results from the surgically treated individuals.

Subsequently, many of these same individuals have had DNA collected and analysed
using GWAS SNP profiling as part of the Busselton study.
Here, we have identified the affected and unaffected individuals in the Busselton study
from their responses in the 1994-95 survey. We have then used the collected GWAS data
on these individuals to identify regions of interest that may be associated with the
incidence of Dupuytren’s disease in this population. Whilst the population is somewhat
small for a GWAS study, the information gained from this approach will be integrated
with the findings from Chapter 2 to potentially identify genes of interest using two
separate approaches.

3.2 Methods
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Ethics approval for this study was obtained from the Busselton study committee and
relevant institutional ethics committees (University of Western Australia Human Research
Ethics Committee – RA/4/1/2203).
3.2.1 Survey Responses
In 1995 two questions were included in the Busselton community survey as outlined
above. Out of a complete set of responses to the questionnaire, 409 individuals responded
positively to question one, whilst only 48 positive responses to question 2 were received.
Thus a cohort of 48 adults who had recorded a surgical history for Dupuytren’s disease
(DD) was identified; 42 of them provided blood samples.

Of the 409 participants whose questionnaire provided suggestive evidence of palmar
bands, 360 (ie 90 percent) gave blood for laboratory analysis. The analysis focused on
those with a surgical history of DD as the positive affected cohort.
3.2.2 Statistical power for association analysis
Power analysis for the 513,727 Busselton GWAS SNPs available after quality control with
suggestive genome-wide association after correction for multiple testing (i.e. requiring a
p-value threshold of 1.0 x 10-4), with a 10% prevalence rate, and a minor allele frequency
of 0.19 for the risk variant demonstrates that we expect 80% power for a SNP that has an
odds ratio ≥ 1.67 for 409 developed thickened band cases and 4,262 controls and an odds
ratio ≥ 4.0 for 48 positive cases and 4623 controls. Although these odds ratios would be
considered large for common variants from GWAS, these results were primarily applied
to prioritize interrogation of WES data for Dupuytren’s disease. Gene- and pathwaycentric burden tests were employed to compensate for low statistical power in variants
that might have been missed due to low copy number.
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3.3 Results
Both a dominant model (table 3.1) and additive model (table 3.2) were used to identify
SNPs associated with DD in the Busselton cohort. The dominant model assumes that the
risk of the disease phenotype is equivalent between heterozygotes and homozygotes with
the relevant polymorphism. Inheritance of Dupuytren disease within families follows a
dominant model with incomplete penetrance. The additive model, in contrast, assumes
increased risk in homozygous compared to heterozygous SNP presence (linear increase
therefore a homozygous affected would have 2x the effect of a heterozygous affected).
Using an arbitrary cut-off p value of 5 x 10-5 20 SNPs and 39 SNPs were identified for
the dominant and additive models respectively (Tables 3.1, 3.2). Using UCSC Genome
browser (https://genome.ucsc.edu/) a search for proximal genes was then conducted to
identify potential genes of interest. A distance cut-off from the SNP of 50MB was used
for identifying associated genes. Within 50MB of the SNPs identified there were 17 genes
and 5 long non-coding RNAs (LINCs) for the dominant model (table 3.1). There were 18
genes and 2 LINCs within this distance for SNPs identified using the additive model (table
3.2).

No genes identified using this methodology were identified that were also identified in the
previous family study using whole exome sequencing (Chapter 2). However, genes with
roles closely related to those identified in the previous family WES study were identified,
including genes with known functions in immune responses, matrix remodeling and
vascularization. This may implicate these processes in the molecular pathology of DD and
are discussed in detail below.
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Table 3.1:Single nucleotide polymorphisms (SNPs) identified as being associated with DD in the Busselton population
using the dominant model. Table shows chromosomal location, SNP (A1) at this location, Odds ratio (effect size of the
SNP identified), p value (not corrected) and genes identified at this location using UCSC genome browser together
with other features of that region (within 50MB DNA of SNP).

CHR SNP

1 rs1938506

1 rs4650729

BP

A1

185647122 C

185645949 A

OR

1.676

1.67

P

Genes

Other

7.06E-

LINC01036,

06

LINC 01037

8.21E-

LINC01036,

06

LINC 01037
SDE2,

1.42E- LEFTY1,
1 rs2755095

224266458 A

1.669

05 LEFTY2
2.54E-

1 rs10917756 161688944 T

0.6072

05 RGS5, NUF2
SDE2,
3.07E- LEFTY1,

1 rs11590226 224269676 G

1.676

05 LEFTY2
3.58E- SSUH2

3 rs926147

8665221 G

1.627

05 (intragenic)
1.59E-

4 rs2629722

4 rs7664705

19601579 C

178808597 T

0.5818

1.64

05 none
3.62E-

LINC01098,

05

LINC01099

4.15E4 rs12642843 168828864 T

0.6028

05 none
Other
1.79E-

6 rs10946808

26341366 G

0.6045

05 HIST1H1D

histone
proteins
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Other
3.62E6 rs9358913

26347383 G

0.6135

05 HIST1H1D

histone
proteins

4.22E- CREB5
7 rs7806362

28353228 A

0.6222

05 (intragenic)
2.80E- ZMIZ1

10 rs704014

80502780 A

0.5601

05 (intragenic)
8.93E- CYP27B1

12 rs8176350

56443115 A

7.463

06 (intragenic)
1.64E-

14 rs1245384

26683529 G

15.11

05 mir4307
2.14E- GALNT16

14 rs1016692

68858656 G

1.654

05 (intragenic)
3.52E-

15 rs10520669

86160186 T

1.796

06 NTRK3

LINC00052

4.86E15 rs596726

60966570 C

0.5897

06 TPM1, TLN2
3.49E- RBFOX1

16 rs7359428

7597028 A

1.908

05 (intragenic)
2.76E- MAVS

20 rs6084497

3778474 C

0.6093

05 (intragenic)

MGC15885
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Table 3.2: Single nucleotide polymorphisms (SNPs) identified as being associated with DD in the Busselton
population using the additive model. Table shows chromosomal location, SNP (A1) at this location, Odds ratio (effect
size of the SNP identified), p value (not corrected) and genes identified at this location using UCSC genome browser
together with other features of that region (within 50MB DNA of SNP).

CHR

SNP

BP

A1

OR

15

rs16944840

89146352

C

4.841

18

rs8085949

38534982

A

5.477

15

rs8027126

89138090

T

4.772

18

rs9963027

38540181

C

5.852

11

rs4944893

73848928

T

3.354

11

rs11602340

73852880

G

3.305

3

rs17071419

64730279

C

9.58

18

rs1790605

65673014

G

3.64

18

rs1469857

65679994

A

3.593

2

rs1902156

84431095

T

3.709

PYHIN8

rs11985018

23667806

T

2.985

2

rs11904045

84472093

T

3.697

P
1.91E06

Gene

LINC00907

06

06

BLM (intragenic)

2.82E-

LINC00907

06
3.55E-

KCNE3

06

(intragenic)

4.32E-

KCNE3

06

(intragenic)

4.67E06
5.50E06
6.35E06
7.31E06

Information

BLM (intragenic)

2.04E-

2.44E-

Other

ADAMTS9-AS2

CD226

CD226

none

7.44E-

RP11-

06

175E9.1

7.79E06

none

69

8

rs10866835

23663678

C

2.979

9

rs10117511

20291210

A

6.337

18

rs1790942

65692568

G

3.589

22

rs133681

47145275

G

2.757

3

rs7613386

136942607

A

2.769

3

rs17071334

64686344

T

6.85

5

rs10057902

93838641

T

5.855

9

rs16938009

20298956

G

6.017

4

rs10516161

57631492

G

3.829

5

rs2656984

82224868

C

4.297

1

rs11590737

157210445

G

3.083

8

rs878422

142397180

T

2.853

6

rs13213906

68284933

C

2.612

8

rs9650576

142415238

T

2.832

6

rs9454149

68213259

G

2.617

7.82E-

RP11-

06

175E9.1

7.99E06
8.20E06
8.92E06
1.03E05
1.18E05
1.22E05
1.42E05
1.60E05
2.00E05
2.09E05

MLLT3

CD226

none

none

ADAMTS9-AS2

KIAA0825

none

IGFBP7

none

PYHIN1

2.24E-

LINC01300

05
2.33E05

none

2.47E05
2.62E05

none

LINC01300
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8

rs10503582

16475833

C

2.741

21

rs2032308

31287785

G

2.846

8

rs10088377

23659124

G

2.895

11

rs360145

9745546

T

7.1

10

rs675410

100340312

A

3.51

1

rs1308343

43401913

T

5.849

14

rs1955967

43581549

A

2.866

6

rs7752524

25418564

G

2.939

22

rs138475

45408904

G

2.556

10

rs502195

100349453

T

3.438

11

rs585197

88867269

C

2.597

6

rs12523876

82643081

T

3.394

2.76E05
2.95E05

none

KRTAP21, TIAM1

KRTAP
cluster

3.26E-

RP11-

05

175E9.1

3.37E05
3.57E05

SBF2-AS1

HPSE2

3.63E-

FAM183A,

05

EBNA1BP2

3.66E-

RP11-

05

305B6.3

3.71E05
3.85E05
4.07E05
4.27E05

LPRC16A

GRAMD4

HPSE2

NOX4

4.98E-

RP11-

05

379B8.1
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3.4 Discussion
3.4.1 Findings in other linkage and genome wide association studies for
Dupuytren’s disease
Previous genetic studies in Dupuytren’s disease have targeted those genes involved in the
regulation of fibroblast activity, including pathological collagen production and lattice
contraction in the extracellular matrix, as well as apoptosis and proliferation and alpha
smooth muscle actin expression (Vi et al., 2009; Shih et al., 2012). One previous GWAS
study has been conducted using a large population including those affected (960) and not
affected (3117 controls) with Dupuytren’s disease (Dolmans et al., 2011). This study
combined with three additional independent case series comprising a total of 1365
individuals affected with Dupuytren’s disease and a further 8445 controls from Germany,
the United Kingdom and the Netherlands to identify 35 SNPs most strongly associated
with Dupuytren’s disease. From these large populations this study identified 11 SNPs
from 9 regions of interest that were validated in two independent replication populations.
Of particular interest, within 6 of these regions genes known to be involved in a single
signaling pathway, the WNT signaling pathway, were located. This pathway has
previously been implicated in other studies investigating the pathogenesis of fibrosis in
Systemic Sclerosis, Idiopathic Pulmonary Fibrosis and Dupuytren’s disease, although to
date no strong functional evidence exists to link dysfunctional Wnt signaling to
progressive fibrosis (Moon et al., 2004; Vlad et al., 2008; Konigshoff et al., 2009;
Bhattacharyya et al., 2012).
Despite the large population size and independent replication populations, the previous
GWAS study of Dupuytren’s disease has provided support for a role of specific genes but
no actual mutations involved in Dupuytren’s pathogenesis were identified and validated.
This is a common limitation of the GWAS approach and supports the use of multiple
research methods combined with the GWAS approach to identify disease-causing
mutations.
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3.4.2 Possible role for genes in regions of interest from the Busselton GWAS study
None of the same SNPs identified previously by Holman et al were identified in this study
of Dupuytren’s disease although this may be solely due to limited statistical power of the
current study. Of the genes located within regions showing positive association with SNPs
using the p-value cut-off none have previous evidence directly linking the gene to DD.
Howevere there were genes identified that have key biological functions related to fibrosis
and may therefore play a role in DD.

SDE2 is a Telomere maintenance homologue (S Pombe) on chromosome 1. An important
paralog of this gene is SF3A3 which may be responsible for development of intrahepatic
cholangiocarcinoma (Wang et al., 2006). This gene has been identified among related
genes by comparison with normal liver tissues, but no known disorders have been found
for the SDE2 gene. Dupuytren’s disease has a reputation for an association with high
alcohol intake, which seems to imply a metabolic basis that could potentially be related to
alcoholic cirrhosis (Wolfe et al., 1956). Hnanicek et al (2008) found a high incidence of
chronic liver disease in Dupuytren’s patients but demonstrated a lack of association with
iron metabolism in Dupuytren’s disease.

These findings, however, have not been

confirmed consistently through large epidemiological studies, and there has been no
positive relationship with other forms of hepatic fibrosis including haemachromatosis and
post-hepatitis cirrhosis. Stremmel et al (1988) identified differing abnormalities in
estrogen, androgen and insulin metabolism in idiopathic haemochromatosis compared
with alcoholic liver disease, findings that could be relevant in Dupuytren’s pathology
(Stremmel et al 1988).
LEFTY2 represents Left–Right determination Factor 2 and is a member of the TGF
superfamily. The work of Bayat (2003) and many others has confirmed that TGF family
members are multifunctional including a role in wound healing and fibrosis, although only
TGFRI polymorhisms were significantly different in genotype frequency distributions
between Dupuytren’s patients and controls. There was no statistical difference in genotype
or allele frequency distributions between cases and controls for TGFBRII and TGFβRIII
SNPs (Bayat et al,2003).
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The SSUH2 gene is a transcription regulator in Notch signaling and binds specifically to
methylated DNA. It binds to the oxygen-responsive element of COX412 and activates its
transcription under conditions of hypoxia (4% oxygen). (Aras et al 2012; Funayama et al,
2015). Since hypoxia is a known cause of tissue fibrosis and age-related peripheral
vascular changes, diabetes and smoking are commonly associated with the development
of progressive palmar fibromatosis there could well be a role for this gene in the
pathogenesis of Dupuytren’s disease.
NTRK3 (neurotropic tyrosine kinase receptor type 3) encodes a member of the
neurotrophic tyrosine receptor kinase (NTRK) family. This kinase is a membrane-bound
receptor that, upon neurotrophin binding, phosphorylates itself and members of the
MAPK pathway. Signaling through this kinase leads to cell differentiation and may play
a role in the development of proprioceptive neurons that sense body position.
In South America it has been investigated in association with Chaga’s Disease.
Trypanosoma cruzi infestation promotes neuronal and glial cell survival (in vitro) by
inhibiting TicC-induced apoptosis (Rodriguez and Mehlen, 2010).
RBFOX1 has been associated with small joint osteoarthritis of the hand, familial
neurodegenerative diseases, spino-cerebellar ataxia type 2, and in Japan it has been
identified with primary biliary cirrhosis (Joshita et al., 2010) Its involvement with epilepsy
could be significant in those cases that exhibit a Dupuytren’s phenotype, but the
association of Dupuytren’s with epilepsy has not been consistently reported or confirmed.
3.4.3 Comparison of results from the Busselton and family studies
From the WES analysis of affected family members (Chapter 2) and the GWAS
population study from Busselton there appears to be no overlap of genes identified from
both cohorts. The two studies also do not provide overlap with other published studies
looking at the genetic basis of Dupuytren’s disease. However in a population of unrelated
individuals it would be expected that variable expression in terms of age of onset, degree
of hand involvement (unilateral/bilateral), clinical evidence of digital contracture, and rate
of progression of fibromatosis, gender differences, association with other disease profiles,
would involve a variety of genetic pathways and genes. It is not therefore completely
surprising that the genes obtained from such a diverse small population do not correspond
with those identified from other studies.
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Interestingly when comparing the family WES and Busselton study results there does
appear to be overlap, whilst not in genes, but in the biological pathways that may be
implicated. For example, in the WES family study (Chapter 2) a number of potential genes
of interest that were identified had clear roles in vascularization/angiogenesis and there
were also pro-inflammatory/immune modulating genes identified. In the investigation
using the Busselton population data, CD226, PYHIN1 and MAVS genes which were
proximal to identified SNPs all have roles in the immune system. In particular PYHIN1
and MAVS are both implicated in the interferon induced anti-viral response, which is of
interest given that previous reports have associated viral infection to Dupuytren’s disease.
There are other very strong candidate genes identified in the list of genes proximal to the
SNPs identified. This includes ZMIZ1, which is important in androgen receptor signaling
and also the regulation of SMAD3/4 expression. SMAD3/4 in particular are well-known
to be important in fibrosis and

their direct involvement in regulation of fibrosis suggests

a good candidate for Dupuytren’s disease.

Genes with important roles in matrix

production and turnover were also identified including HPSE2 (a heparanase with no
enzymatic activity but likely a regulator of other heparanase activity), TLN2 (Talin 2) and
interestingly ADAMTS9-AS2. AS genes are anti-sense genes that are only recently
described. The transcription of these genes appears to regulate the expression of the related
gene, in this case ADAMTS9. The ADAM family of proteins is large and some have
already been implicated in DD in previous studies.
Finally, tropomyosin I (TPM1) is also a potentially interesting candidate for further
investigation. Tropomyosin is critical in regulating actin-myosin interactions and
contractile activity. It is clear this activity could be important in the progression of DD.
Despite this study being underpowered the candidate genes identified in proximity to
SNPs associated with the DD phenotype do appear to have functional roles that are
important in DD pathology. However, the fact the study is underpowered reduces the
significance of any individual finding and further validation that these genes may be
involved is critical. This also highlights the difficulty of GWAS type approaches, since
these genes are only implicated by proximity to these SNPs in the same way as WNT
pathway genes were implicated in the much larger GWAS conducted by Dolmans et al
(2011). Therefore, whilst these genes are potentially of interest there is no clear functional
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or expression difference to verify that the genes identified are altered in DD affected
patients. The finding that many of these genes have roles in pathways also identified in
the WES study (Chapter 2) and in other studies of DD, including angiogenesis and the
likely role of hypoxia/circulation in DD pathology, support a non-fibroblast origin of DD
pathology that has previously been hypothesized.
3.4.5 Significance of environmental factors and genetic susceptibility
Numerous environmental and genetic studies of the fibromatoses and related pathologies
have produced evidence to support the familial nature of these conditions in the majority
of cases. Inheritance of a susceptibility to develop a Dupuytren’s phenotype after middle
age appears to follow an autosomal dominant pattern with variable expression and
occasionally incomplete penetrance. The ethnic differences which demonstrate consistent
but widely different incidence of Dupuytren’s pathology are most obvious between white
Caucasians from Northern Europe and black Africans. The same difference in incidence
exists between black and white communities living in the same country such as the United
States. This would strongly suggest a predetermined genetic susceptibility that exists
within the white population and to a far lesser degree among African Americans. A similar
discrepancy exists between Europeans and most Asian populations.
With some allowance to be made for differences in lifestyle factors such as diet, climate,
education, employment and living conditions, it is obvious that even the susceptibility to
develop a particular disease must be genetically determined. From the many genetic
studies that have attempted to identify genetic pathways and specific candidate genes
responsible for the progression of fibrosis in a Dupuytren’s phenotype it has become
obvious also that there must be several genes and pathways involved in this pathology,
the spectrum of such combinations accounting to some extent for the variations observed
in age of onset and degrees and speed of progress of the disease.
The experience of many epidemiologists tends to favour a range of environmental factors
which might trigger the onset of Dupuytren’s, many of which can be related to the ethnic
variations and differences in incidence observed (Geohegan et al., 2004; Gordon,1954).
Lifestyle factors such as smoking and alcohol abuse, both of which have been associated
with significant levels of Dupuytren’s in certain populations, tend to be related to gender,
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age, generation and employment, factors which affect the expression of this disease to a
variable extent in different communities (Godtfredsen et al., 2004; Khan et al., 2004).
Nevertheless, as with a number of co-morbidities that impose further metabolic and
immunologic stresses on molecular function, the importance of environmental impact
upon a susceptible organism must be significant.
“Transforming growth factor  is the pre-eminent signal for connective tissue synthesis,
and is considered as a ‘core pathway’ in both normal wound healing and pathological
fibrosis” (Bhattacharyya et al., 2012). However, the molecular pathways responsible for
activation and progressive proliferation of fibroblasts and myofibroblast differentiation
can be expected to involve a number of intrinsic and extrinsic cellular factors, including
dysregulated beta-catenin and Wnt signaling glycoproteins (Vlad et al 2008), Akt and
integrin pathways, and aberrant or dysregulated TGF-beta expression. Dysregulation may
also be stimulated external to the fibroblasts which are clearly the drivers of the
progressive disease.
The role played by TGF receptors in the genetic susceptibility to Dupuytren’s disease
has previously been investigated with a statistically significant difference of TGFbR1
polymorphisms in DD in the recessive model. (Bayat 1;2003 These authors also conclude
that “DD appears to be a complex olygenic rather than a monogenic condition that
segregates into multiple modes of inheritance”) (see also Burge P Genetics of DD Hand
Clinics 1999;15(1):63-72) re proposed autosomal recessive mode of inheritance). While
the recessive model is not in agreement with the majority of observed series reported with
familial Dupuytren’s disease the suggestion of a complex polygenic inheritance involving
several pathways is readily accepted in light of the variable expressivity and degree of
phenotypic progression (Hu et al., 2005; Gudmundsson et al., 2001). The role of TGF
beta2 in this pathology has been investigated also by Zhang et al (2008) with ‘gene
expression analysis’; different isoforms of TGF-beta have been reported to have both
profibrotic and antifibrotic effects.
Genetic linkage and whole genome association studies have also been reported,
significantly associated loci being compared with the results of gene expression profiling
studies (Shih et al., 2012). Two such genes, MAFB and PRKX (protein kinase X-linked),
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were highlighted by both studies. PRKX contains a SNP that shows a positive association
with Dupuytren’s disease (Li X. et al., 2011). The expression of MAFB in Dupuytren’s
disease has been investigated by Lee et al (2006) who noted its complete absence in
adjacent control fascia. MafB was found to be of particular interest because of its
prominent role in tissue development and cellular (myofibroblast) differentiation, and a
significant co-location in some cells with alpha-smooth muscle actin (Lee et al., 2006).
As with the puzzling array of genetic influence in the pathogenesis of Dupuytren’s disease,
the combined effects of aging, associated changes in immune response, hormones and
metabolism, together with the effects of co-morbidities such as diabetes mellitus, provides
a wide range of environmental factors to influence the clinical outcome. Such a ‘pot
pourri’ of active ingredients with possible influence on the development of a highly
recognizable immuno-histo-chemical pathology would suggest, however, that the
molecular pathway, once established, is little affected by environmental factors.
Nevertheless, the environmental factors may play a very significant role in the
establishment of the disease and therefore confound genetic studies aimed at identifying
causative mutations or polymorphisms.
3.4.6 Limitations of this study
GWAS studies require large populations of both affected and non-affected individuals to
be effective in isolation. The power of the Busselton study in relation to the current
investigation is limited by the small number of identified affecteds – this does not
represent a large enough population with Dupuytren’s disease for GWAS. It was,
however, useful to provide a database for associations in the population study with
possible areas of interest in common with mutations derived from the whole exome study.
The DNA obtained from the Busselton 2006 population study encompassing a broad
investigation of five thousand essentially unrelated adults became available for specific
genetic analysis. Forty-eight adults were positively identified through the detailed
questionnaire as having undergone surgery for Dupuytren’s disease, the clinical diagnosis
thereby confirmed.
GWAS on this cohort were considered inadequate for statistical analysis or for comparison
with results of previous studies, eg Dolmans et al, 2011. The Busselton results, however,
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produced a list of mutations with an OR >1.0, and with locations identified to a number
of chromosomes of interest. Our current study has found it useful to focus on these regions
to determine associations with genes from the WES of family members as reported in
Chapter Two. Other than small study size making the approach underpowered the other
significant limitation of this approach is the inability to identify potential functional
changes that can be further interrogated. Had there been direct overlap in genes identified
in the WES study (Chapter 2) it may have been feasible to progress further investigation
on a common candidate using functional and genetic approaches. However, in this study,
whilst a number of genes with relevant functions were identified as being close to
polymorphisms with a positive association with DD, there was no insight into whether
there were expression of functional changes in the identified genes. This limits the ability
to further interrogate these findings and is a significant limitation of all GWAS studies.

Taking into account the broad spectrum of clinical involvement as exhibited by the
variable Dupuytren’s phenotype found among members of one family, and the
unpredictable nature of disease progression, the variable severity of this disease may be
due to different levels of interaction between genetic and environmental factors possibly
triggering different levels of activated/suppressed signaling pathways.
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CHAPTER 4
Aim 3
Investigation of the presence of rare mutations in unrelated individuals with the severe
Dupuytren’s phenotype by whole exome sequencing, and comparison with findings from
affected family members and the community-based study of unrelated affecteds.

4.1 Introduction
The previous work using Whole Exome Sequencing of family members and data from a
population based study has identified a small number of candidate genes that may
contribute to Dupuytren’s pathology. To further investigate the significance of specific
genes to molecular changes underlying the development of this pathology and verify the
range of genes involved it was considered advantageous to investigate the presence of rare
mutations in unrelated individuals with severe Dupuytren’s disease using whole exome
sequencing.

Whole exome sequencing is considered appropriate for the investigation of inherited
pathology within a family cohort. The initial sequencing of DNA from family members
with Dupuytren’s disease (Ch 2) has identified mutations common to all individuals; this
number was reduced by a selection process which identified candidates which responded
to a functional data base and excluded a large number of variants found in the general
population and considered unlikely to be specific to this disease.
To further investigate the potential validity of these candidates the DNA from two
unrelated individuals with a Dupuytren’s phenotype considered to be aggressive and
severe has been included in this study for whole exome sequencing. Mutations identified
from their DNA are then matched against those selected from the family affecteds to
further reduce the possible mutations considered to have functional involvement in
Dupuytren’s disease.

4.2 Methods
The protocols for collection of DNA and Whole Exome Sequencing were followed as
described in Chapter 2.
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Two unrelated individuals with aggressive disease were also included in this study. They
were assessed as severe cases by the following criteria; early age of onset (40 or younger),
bilateral hand involvement with Dupuytren’s disease, known positive family history of
Dupuytren’s disease, and progressive active palmar fibromatosis with digital contractures.
Analysis of data followed the protocols as described in Chapter 2.
4.2.1 Pathway analysis
For pathway analysis a combined gene list of all candidate genes of interest identified
from all three studies (family WES, Busselton GWAS and Severe brother study) was
generated. The gene list was uploaded to the Database for Annotation, Visualization and
Integrated Discovery (DAVID) version 6.8 (1) to look for gene ontology groups and
pathways enriched from the genes of interest. For the gene ontology analysis, the groups
“GOTERM_BP_DIRECT”, “GOTERM_CC_DIRECT” and “GOTERM_MF_DIRECT”
were selected and run with an EASE score of 0.2, a modification of the Fisher’s Exact test
to measure whether independent groups can fall into one of two mutually exclusive
categories. Resulting data was exported to excel. Pathway data was analysed in a similar
way, using an EASE score of 0.2 and the “KEGG_PATHWAY” option. Resulting data
was exported to excel, and images of pathways with genes involved also exported (Huang
et al, 2008).

4.3 Results
The following table lists the genetic mutations identified as occurring in both the severe
Dupuytren cases as heterozygous mutations.
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Table 4.1:Non-synonymous polymorphisms identified in two related individuals with severe Dupuyren’s disease
List of mutations identified in both individuals and that had a predicted deleterious effect on the protein as medium or
high for impact severity. These were identified and screened as described (methods section), with the focus on
mutations likely to have a higher level of effect given that these patients were early onset and exhibited a severe
progressive disease pattern.
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To assess this larger list of mutations for possible functional significance and correlation
to the genes identified in previous chapters (2 and 3) gene set enrichment analysis (GSEA)
was conducted using the online DAVID tool (Huang et al, 2008). GSEA provides a
method to identify pathways and processes that are significantly over-represented in entity
lists. This can be help identify important themes in large datasets and overcomes some of
the limitations of low powered studies that cannot identify significant changes at the
individual gene/polymorphism level.
Pathways identified as being significantly over-represented in the combined studies in
this thesis using gene ontology categorization include cell morphogenesis and protein
turnover pathways (Table 4.2). Other pathways that were potentially enriched (but do
not reach statistical significance) include cell proliferation, migration and apoptosis
(Table 4.2).
Table 4.2: Gene ontology enrichment analysis. Processes including heart morphogenesis and cellular proliferation
and apoptosis are enriched in the candidate gene lists identified in this study (table shows pathway identified by, % of
pathway genes enriched in the target gene list, P value and genes from the target gene list identified in each pathway.

Term ID
Term Name
GO:0003007 heart morphogenesis
GO:0061157 mRNA destabilization
GO:0051865 protein autoubiquitination
positive regulation of protein
GO:0001934 phosphorylation
GO:0006623 protein targeting to vacuole
GO:0000902 cell morphogenesis
sulfur amino acid metabolic
GO:0000096 process
GO:0030855 epithelial cell differentiation
hyaluronan metabolic
GO:0030212 process
glutathione biosynthetic
GO:0006750 process
negative regulation of cell
GO:0008285 proliferation

%
PValue
Genes
2.362205 0.016698 ZMIZ1, TBX1, LEFTY1
1.574803 0.036595 METTL3, MEX3D
LRSAM1, TRIM17,
2.362205 0.038386 TRIM21
MAVS, NTRK3, TBX1,
3.149606 0.04433 STK4
1.574803 0.048496 VPS13C, PIK3R4
NOX4, SHROOM3,
2.362205 0.056509 STK4
0.066076 BHMT, GCLM
2.362205 0.069931 TOLLIP, TBX1, ACTL8
1.574803 0.071864 ITIH4, ITIH3
1.574803 0.094663 GGT6, GCLM
NOX4, ENPP7,
CYP27B1, BCHE,
4.724409 0.099541 IGFBP7, STK4
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positive regulation of cell
GO:0030335 migration
positive regulation of
GO:0043065 apoptotic process
GO:0048844 artery morphogenesis
GO:0002576 platelet degranulation
response to interferonGO:0034341 gamma
GO:0006936 muscle contraction
GO:0007569 cell aging
GO:0048589 developmental growth
GO:0003341 cilium movement

GO:0007155 cell adhesion
GO:0007389 pattern specification process
GO:0016925 protein sumoylation
cellular response to fibroblast
GO:0044344 growth factor stimulus
GO:0043588 skin development

NTRK3, ITGA6,
3.149606 0.106131 SEMA3G, MYLK
NOX4, NTRK3, ITGA6,
3.937008 0.115882 TGM2, STK4
1.574803 0.122382 ZMIZ1, TBX1
2.362205 0.133774 LEFTY2, ITIH4, ITIH3
1.574803
2.362205
1.574803
1.574803
1.574803

0.138609
0.142209
0.143952
0.143952
0.154539

CYP27B1, TRIM21
DYSF, TPM1, MYLK
NOX4, ZMIZ1
ZMIZ1, ASPM
CFAP53, DNAH1
CLCA2, ITGA6, TLN2,
COL6A5, IGFBP7,
4.724409 0.155893 CD226
1.574803 0.159783 SHROOM3, TBX1
2.362205 0.163759 BLM, RANBP2, SENP5
1.574803 0.170176 TBX1, GCLM
1.574803 0.190582 ITGA6, SLITRK5

Using KEGG pathway analysis significantly enriched pathways were for Huntington’s
disease and Focal adhesions (Table 4.3).
Table 4.3:KEGG pathway analysis. Pathways enriched in the gene lists identified in this study include Focal
adhesions and Huntingtons disease (table shows pathway identified by KEGG, % of pathway genes enriched in the
target gene list, P value and genes from the target gene list identified in each pathway.

Category

Term Name

KEGG_PATHWAY Huntington's disease
KEGG_PATHWAY Focal adhesion
KEGG_PATHWAY Mucin type O-Glycan biosynthesis

%

PValue

Genes
TGM2, CREB5,
3.15 0.030359 DNAH1, DCTN1
ITGA6, TLN2,
3.15 0.048892 COL6A5, MYLK
GALNTL6,
1.575 0.172553 GALNT16

The genes enriched in the focal adhesion pathway are highlighted in Figure 4.1 in the
context of the whole pathway used for this annotation (Fig. 4.1). Genes identified in this
pathway originate from the family WES study (COL6A5), the Busselton study (TLN2)
and the WES of the severe affected individuals (ITGA6). This indicates that this
pathway has a gene that may be disrupted in each of the studies and points to a potential
common pathway that may in part underpin Dupuytren’s disease.
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Figure 4.1:Focal Adhesion Pathway genes implicated in DD The focal adhesion pathway is over-represented in the
combined lists of target genes identified in the genetic studies in this thesis. Figure shows focal adhesion pathway
with genes identified in the genetic studies highlighted with red star symbol.

4.4 Discussion
The reason for investigating the genetic profile of unrelated individuals with severe/
aggressive

Dupuytren’s

phenotype

was

the

potential

to

identify

mutations

(polymorphisms) in genes previously identified but that would be rare mutations (since
severe Dupuytren’s disease is very uncommon in comparison to late onset disease) and
that these mutations would have a more deleterious effect on protein function, thereby
leading to the earlier onset and excessive nature of the disease in those with the severe
phenotype. When restricting the list of non-synonymous mutations identified in both
individuals with severe disease to those with a predicted moderate/severe effect on protein
function, heterozygous and in less than 0.1% of the population, a total of 93
polymorphisms were identified. This is a large number of potential candidates and is an
interesting observation given that these are rare non-synonymous mutations identified to
be in common in two unrelated individuals. Despite this large number of potential
candidate genes, as in the previous studies (Chapters 2 and 3), no overlap in candidate
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genes was observed in the list of genes obtained from the unrelated individual analysis
when compared to the previous studies.
4.4.1 Identification of potential target genes
Given the extensive list of potential candidate genes identified it is unsurprising that there
are genes of interest with functions that can be hypothesized to be relevant to DD
contained within. There are many different matrix associated proteins with functions that
are likely or have been well described to be important in fibrosis, including Integrins
(ITGA6 and ITGA7), members of the ADAMTS family (a disintegrin and
metalloproteinase with thrombospondin motifs family), Collagen genes (including
COL5A1) and cadherin related proteins (CDHR4). All of these genes have key roles in
maintaining and regulating the ECM: cell interactions and are therefore plausible
candidates for involvement in DD given the known pathology of the disease. Similar to
the previous studies presented in Chapters 2 and 3, genes with known roles in immune
responses (for example ITIH4 and LAIR1) and genes important in the regulation of
vascularization (for example ANGPTL4) are also candidate genes that can be
hypothesized to be involved in DD pathology. Interestingly, ANGPTL4 is associated with
Type II Diabetes, which is itself associated with DD, and ANGPTL4 plays an important
role in vascularization and a response to hypoxia, which has previously been hypothesized
to be the underlying cause of DD. However, despite the presence of genes with relevant
functions and polymorphisms predicted to be deleterious, these findings are weakened by
the presence of many other rare polymorphisms in both individuals that were predicted to
be moderately or severely deleterious but occur in genes with roles most likely unrelated
to the disease. This makes interpretation of these findings alone difficult, as would be
expected when using WES on only two unrelated individuals. However, in the context of
the previous studies and combining the findings from these studies it becomes apparent
that there are specific pathways that may be common across the individuals that have been
investigated and this may provide insight into the pathogenesis of DD.
4.4.2 Pathway analysis of combined genes of interest
Given the lack of direct overlap between these studies a pathway analysis was used to
identify any pathways that may be in common, albeit affected by polymorphisms in
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different genes that may underpin DD. Using this pathway analysis focal adhesions
appeared to be significantly enriched. Interestingly this pathway contained genes
identified in each of the three independent studies, suggesting that in each study, family,
Busselton and severe unrelated individuals, there was a gene identified of interest that is
involved in focal adhesions and the signals generated by them.Focal adhesions are a type
of adhesive contact between cells and the extracellular matrix. They are critical structures
that facilitate communication between cells and the environment and can be involved in
biomechanical sensing and signaling (for example changes in matrix physical properties
such as stiffness) as well as biochemical signaling (mediating biological signals for
cell:cell and cell:matrix communication). Focal adhesions are critical to many different
processes and the intracellular signaling stimulated by focal adhesions is mediated by
Focal adhesion kinase (FAK). FAK has been demonstrated to be critical to TGFb signaling
and in the induction of profibrotic genes in response to TGFb signaling (Liu et al 2007).
More recently targeting FAK has been demonstrated to ameliorate fibrosis in a number of
animal models of fibrosis, suggesting this signaling pathway is critical (Lagares, 2013;
Kinoshita K, 2013). Therefore strong evidence exists for the importance of focal adhesions
in fibrosis and this suggests the identification of this pathway potentially being affected
by polymorphisms identified in the studies presented here is important to follow-up with
further work to characterize the impact of these polymorphisms and the role they may play
in DD.
4.4.3 Summary
To identify gene mutations common to unrelated individuals exhibiting evidence of
Dupuytren’s phenotype with a clinical picture suggestive of severe or aggressive disease,
the DNA from two males with early-onset, progressive, bilateral palmar fibromatosis and
a positive family history of Dupuytren’s disease was submitted to analysis by whole
exome sequencing. No genes directly linked to the previous studies were identified.
However, the importance of focal adhesions has been implicated by pathway analysis and
this warrants further investigation. In addition, other polymorphisms with clear likely
relevance to DD warrant further investigation from those identified in individuals with a
severe disease phenotype. Further sequencing from other unrelated individuals with
severe disease may facilitate identifying the likely causative mutations.
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CHAPTER 5
Aim 4 To investigate the functional consequences of the putative mutations identified in
Aims 1-3 on fibroblast phenotype and pathobiology with relation to Dupuytren’s disease.

5.1 Introduction
The aim of this work is to identify functional mutations in genes that contribute to the
pathology of Dupuytren’s disease using genetic methods. However, whilst the genetic
studies may facilitate identification of mutations that are important it is essential that the
impact of these mutations is also tested in appropriate models. Currently there is no animal
model for Dupuytren’s disease and therefore in-vitro models are required to investigate
the impact of mutations on Dupuytren cells. In this study fibroblasts have been isolated
from two patients with Dupuytren’s disease. The cells were isolated from the affected site
(test sample) and an additional tissue sample was taken from the wrist (unaffected control
fibroblasts). A scar-in-a-jar assay was used to investigate collagen I production by both
disease (cord) fibroblasts and control fibroblasts to determine if there were significant
differences in collagen production in vitro using this assay. If significant differences
between disease and control cells can be detected this assay would potentially be suitable
for investigating the effect of identified mutations on fibroblast activity.

5.2 Methods
5.2.2. Scar-in-a-jar model
The functional assays were carried out using a published protocol known as “Scar-in-aJar” with some modifications (Chen et al. 2009). This method involved culturing
fibroblasts, collagen immunostaining, microscopic imaging and semi-automated analysis
of collagen quantitation and orientation.
5.2.2.1. Cell culture and isolation
Tissue samples were collected from consenting participants in Falcon tubes containing
Dulbecco’s Modified Eagle Media (DMEM) with 10% foetal bovine serum (FBS) and
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500UI/ml penicillin and 500µg/ml streptomycin (5% pen/strep) (Life Technologies, USA)
and processed within four hours. Fibroblasts were isolated from fresh tissue by a slightly
modified explant method. (Keira et al. 2004, Tucci-Viegas et al. 2010).
The samples were washed with PBS containing 100UI/ml penicillin and 100µg/ml
streptomycin (1% pen/strep) (four times, 30 seconds each). Samples were then placed in
sterile petri dishes containing DMEM and subcutaneous tissue trimmed using a scalpel
and forceps. The tissue was cut into small fragments (5-10 mm2) and excess media on the
fragments was removed by blotting on a petri dish lid. About 10-12 fragments were
transferred to each petri dish which was marked with perpendicular lines made by a scalpel
to facilitate fragment attachment to the dish with the dermis side placed down. The dish
was left semi-open in the fume hood for 30 minutes at room temperature for the fragments
to adhere to the surface. Six ml of DMEM with 10% FBS and 1% pen/strep was added
gently to the dish and then incubated at 37oC in 5% CO2. The media was changed every
two days and any floating fragments were plated in a new dish. Outgrowths of fibroblasts
were noticed after 7-14 days. When the cells reached 80% confluence the media and tissue
fragments were discarded. The cells were washed with phosphate buffered saline (PBS)
and trypsinized with 0.05% trypsin with EDTA (Life Technologies, USA), then seeded
into a T75 flask.
KF and NF were seeded at a density of 5 x 104 cells/well in 4-chamber slides (Lab-Tek,
ThermoFisher Scientific, USA) in 1 ml of Dulbecco’s modified eagle medium nutrient
mixture F-12 (DMEM/F12, Life Technologies, USA) with 10% fetal bovine serum (FBS,
Invitro Technologies, Noble Park North, Australia) and 1% penicillin/streptomycin (P/S,
GIBCO®, Life Technologies, USA). After 14 hours incubation at 37oC in 5% CO2, KF
and NF media was removed and replaced by 1 ml of Un-stim media (3 wells) or Stim
media (3 wells). The Un-stim media contained DMEM with 1% P/S, 0.5% FBS and 1%
of 100 mM L- ascorbic acid 2-phosphate (Sigma Aldrich, USA). The Stim media was Unstim media containing 37.5 mg/ml Ficoll PM70 (Fc70, GE Healthcare, UK), 25 mg/ml
Ficoll PM400 (Fc 400, GE Healthcare, UK) and 5 ng/ml-1 transforming growth factor
beta 1 (TGFβ1, R & D Systems, USA). The cultured cells were maintained at 37oC in 5%
CO2 for 6 days before starting the staining.
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5.2.2.2. Immunohistochemistry
The immunohistochemistry for COL1A was carried out using the “Scar-in-a-Jar” protocol
(Chen et al. 2009) with some modifications. After 6 days of culturing with Un-stim or
Stim media the media was removed and the cultured fibroblasts washed once with
FluoroBrite DMEM (GIBCO®, Life Technologies, Grand Island, New York, USA).
Samples were then blocked with 3% bovine serum albumin (BSA, Sigma-Aldrich, St.
Louis, Missouri, USA) in FluoroBrite DMEM for 30 minutes at room temperature. The
blocking solution was removed and primary antibody (10AB, monoclonal mouse antihuman collagen type I, Santa Cruz Biotechnology, Dallas, Texas, USA ) diluted (1:1000)
in 3% BSA was added to the cells and incubated at 37oC in 5% CO2 for 90 minutes
followed by one wash with FluoroBrite DMEM. A solution of 4% paraformaldehyde
(Sigma Aldrich, USA) in PBS was added to the cells and incubated for 10 minutes at room
temperature followed by two washes with FluoroBrite DMEM. The secondary antibody
(AlexaFluor 488 goat anti-mouse IgG, Life Technologies, Eugene, Oregon, USA) diluted
(1:500) in FluoroBrite DMEM was added to the cells and then incubated for 30 minutes
at 37oC in 5% CO2 followed by one wash with FluoroBrite DMEM. The nucleolus was
stained for 10 minutes at room temperature with Hoechst (Life Technologies, USA)
diluted (1:1000) in FluoroBrite DMEM. The Hoechst solution was then removed and
followed by two washes with PBS. PBS was removed and coverslips were mounted on
the slides using Prolong Gold antifade mounting solution (Life technologies, USA). Nail
polish was added to fix the coverslips before imaging.
5.2.2.3 Assessment of collagen quantitation
The imaging of the experiments was undertaken using a Nikon inverted research
microscope (TE 300) and the Nikon NIS-Elements software (Nikon, Japan). The entire
well was tiled and scanned using a 4X objective, B2-A (488nm), DAPI (358nm) filter
blocks; and using the same imaging alignments for both the collagen and nuclear staining
(Figure 5.2). The exposure time was set at 300ms for the Hoechst stain and 1s for the
collagen staining (488nm excitation).
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For each well, several rectangular ROIs (3-6) were used to cover as much of the stained
area of the well as possible. The same dimensions and number of rectangles were applied
for both the collagen staining and its corresponding nuclear staining. Each rectangular
area had a binary threshold applied to mark either the cell nuclei or the collagen fibers.
Once the threshold was adjusted to minimize background and ensure an accurate read, the
object count and binary area covered were measured (Figure 5.2). The obtained data was
exported to Excel. For each well, the sum of binary areas obtained from measuring the
collagen staining was divided by sum of its corresponding object count obtained from
measuring the nuclear staining to give an estimation of the amount of collagen secreted
per cell. The collagen per cell obtained from each ROI was used in the statistical analysis.
5.2.2.4 Flourescence resonance energy transfer assay of procollagen
A Fluorescence Resonance Energy Transfer (FRET) assay was carried out to measure
procollagen concentration in cell media using the human pro-collagen type 1, 10000 tests
kit from Cisbio (Cat. No. 63ADK014PEH), according to the manufacturer’s instructions.
16μL of cell media was added to a single well of the 384 well plate, (Greiner 384 low
volume white plates, high base 4-25ul working volume, Cat. No. 784075, Interpath), to
which 2μL of the anti-human procollagen cryptate antibody and 2μL of the anti-human
procollagen d2 antibody was also added. A standard curve was made up the same way,
with the procollagen standards ranging from 0.78-100ng/ml, as well as a negative control
and a cryptate control. Each sample was run in triplicate. The plate was incubated at room
temperature overnight, then read on a BMG Clariostar microplate reader. Microplate
reader settings were as follows: excitation filter – 330nm, emission filters – 620nm and
665nm, integration delay (lag time) 60μs, integration time 400μs, number of flashes – 200,
gain – 2400. For each well, the ratio of the 665nm/620nm was calculated, then the mean
ratio calculated using the triplicate wells for each sample and standard. The delta F% was
then calculated by using the following equation – (ratio of the standard or sample – ratio
negative control)/ratio negative control x 100. The delta F% values for the standard curve
were then plotted, the equation of the line worked out and the procollagen concentration
of each sample calculated.
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5.2.2.5. Statistical analysis
For each experimental condition, the individual data from each ROI for both the
quantitation and the coherency of collagen were used for statistical comparison. Statistical
significance between all experimental conditions was calculated using the Kruskal-Wallis
(non-parametric) test with corrections for multiple testing. Statistical significance between
two selected groups was calculated using the Mann-Whitney U-test (nonparametric). Pvalue < 0.05 was considered significant. All statistical analysis was carried out using
Prism software v.6.0 (GraphPad, La Jolla, CA).

5.3 Results
The scar-in-a-jar model was tested using normal skin fibroblasts from an unrelated
individual and collagen production compared to fibroblasts isolated from a keloid scar.
Keloid scar fibroblasts were used as an example of fibroblasts from a progressive fibrotic
disease and were therefore expected to be similar in characteristics to Dupuytren disease
fibroblasts. In unstimulated conditions normal skin fibroblasts produced minimal collagen
I (Fig 5.3.1a, e), and this was significantly increased when stimulated with TGfb (Fig
5.3.1b, e). In contrast keloid derived fibroblasts produced significantly higher levels of
collagen I without TGFb stimulation (Fig 5.3c, e, f) when compared to normal skin
fibroblasts and also significantly increased collagen I expression in response to TGFb
stimulation (Fig 5.3d, e, f). This was true in two different keloid patient samples tested
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and suggests collagen I production in-vitro is increased in keloid fibrosis derived
fibroblasts when compared to normal skin derived fibroblasts.
The same experiment was then conducted using cells derived from two patients with
Dupuytren’s disease and cells
isolated from the cord and
wrist (disease and control
respectively). Similar to the
observations with normal skin
fibroblasts neither control nor
disease fibroblasts produced
significant levels of collagen I
in normal culture conditions
(Figure 5.3.2 a-d). However in
response to TGFb stimulation
all cells increased collagen I
production significantly (Fig
5.3.2 e-h).

Figure 5.3.1: Collagen quantitation in scar-in-a-jar model with normal skin and
keloid scar fibroblasts
Collagen I immnostaining and nuclei staining (green and blue respectively) for normal skin unstimulated (NF1US) and stimulated (NF1-S) fibroblasts (a, b) and keloid unstimulated (KF-US) and stimulated (KF-S)
fibroblasts (c, d). Keloid fibroblasts produce significantly more collagen in vitro without stimulation when
compared to normal skin fibroblasts (e, f)
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Figure 5.3.2:Collagen quantitation in
scar-in-a-jar model with fibroblasts
from the wrist (control) and dupuytren
cord (test).
Collagen I immunostaining (green) and nuclei
(blue) using unstimulated conditions and
fibroblasts from patient 1 cord (a) and wrist (b)
and from patient 2 cord (c) and wrist (d). No
significant collagen I production was detected.
After stimulation with TGFb, cells from patient 1
cord (e) and wrist (f) and patient 2 cord (g) and
wrist (h) all expressed significantly higher levels
of collagen I. No differences between control and
disease derived fibroblasts, or between these cells
and those from unrelated normal skin samples,
was observed.

To further investigate collagen production in Dupuytren fibroblasts cell supernatants were
isolated and collagen I synthesis production analysed using a FRET assay (Fig. 5.3.3).
Low levels of Collagen I were produced in unstimulated disease (a) and control (b) cells.
Significantly increased collagen I production was observed after TGFb stimulation (Fig.
5.3.3a, b). However, no difference was observed between control and disease fibroblasts
in either unstimulated or stimulated conditions.
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Figure 5.3.3:FRET assay of collagen I
production by control and Dupuytren
fibroblasts
Collagen

I

production

measured

as

concentration of propeptide in cell media. The
production of collagen I is shown over 6 days
in control (a) and disease (b) fibroblasts in
unstimulated (red) and stimulated (+TGFb)
media (blue). Increased collagen I synthesis is
observed after stimulation with TGFb in both
control and disease fibroblasts. No significant
difference between control and disease
fibroblasts was observed.

Discussion
This investigation was to determine whether the scar-in-a-jar assay and the measurement
of collagen I production could be used as a tool to interrogate the effect of identified
functional mutations on fibroblast function. Since DD, as with other fibrotic disease, is
characterized by excess collagen production it was hypothesized that disease cells would
produce higher levels of collagen than control normal skin fibroblasts. Interestingly,
whilst keloid fibroblasts produced excess collagen when compared to normal skin cells,
this was not the case with DD fibroblasts. In this assay DD fibroblasts appeared to produce
very little Collagen I without TGFb stimulation, as seen with control and unrelated normal
skin fibroblasts. The response to TGFb was also similar between disease and control cells
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with no significant difference in the elevated levels of collagen I produced. The levels of
collagen production were confirmed using two different assays which correlated closely,
suggesting the methodology of detection was valid and that there is no difference in the
DD fibroblast collagen production in vitro when compared to normal skin controls. The
use of alternative methodology or models may have shown a difference in Collagen
production not observed in this study. However, the scar-in-a-jar protocol allows
examination of fibrillar collagen deposition, rather than pro-collagen production (FRET
or Western blot assays) or in the case of qPCR transcription of the gene of interest.
Examining the end product of collagen synthesis (fibrillar collagen) is important since
collagen deposition can be regulated both intracellularly as well as extracellularly.
Therefore by examining the end product of synthesis this protocol allows measurement of
the collagen production most similar to that observed in vivo in the case of fibrotic disease.
This is potentially a better system than inferring increases in ECM collagen deposition by
looking at earlier stages of synthesis that may or may not result in increased deposition.
However, this method is limited, as are many others, by the investigation of de novo
matrix production rather than mimicking the production of collagen by cells already
within a matrix, as occurs in vivo.
The findings in this study are potentially interesting and important for a number of
reasons. First, it is clear that other skin fibrotic disease such as keloid does lead to
increased production of collagen I using this assay. This suggests that the fibroblast
activity in keloid disease is at least in part autonomous, as without additional stimulation
keloid fibroblasts produce elevated levels of collagen I in vitro. In contrast the DD cells
do not produce elevated levels of collagen I in vitro, whilst it is clear that excess collagen
deposition occurs in vivo in this disease. Therefore, it is likely that the excess collagen
deposition observed in vivo may be caused by factors other than changes in the fibroblast.
Factors affecting fibroblast collagen production are numerous and have been investigated
in many fibrotic conditions. One key factor is the matrix interaction with the cell itself. It
has been shown that fibroblasts will respond to changes in matrix stiffness, and part of
this response includes changes in collagen production (Wells RG, 2013). Surprisingly, it
appears that increased matrix stiffness stimulates increased collagen production, creating
a positive feedback loop that may in part underpin progressive fibrosis (Duscher D et al,
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2015; Rittie L, 2015). The assays conducted in this chapter were done in-vitro with no
control over the stiffness of the matrix the cells encountered. Therefore, it may be that in
DD it is matrix changes that are important in fibroblast activity and this explains the
absence of differences between control and DD cells observed here. However, tissue
culture plastic, the surface on which cells are grown in this study and many others, has a
stiffness much higher than any encountered in physiological matrices. Thus is may be that
this very high level of stiffness has an impact on fibroblast phenotype. It would be
interesting to pursue further studies of fibroblast activity using matrices designed to reflect
physiological and increased stiffness conditions to determine if this impacts on DD
fibroblasts.
Alternatively, it may be that other cell signals are important in driving fibroblast activity
in DD. There are many inflammatory signals that are known to be profibrotic, but also
recent evidence that epithelial cells, particularly in response to damage, can secrete
profibrotic signals which in the context of normal wound repair promote restoration of the
tissue barrier. However, these signals can be activated for prolonged periods or
inappropriately and lead to excessive scarring or progressive fibrosis in this context.
It is also possible that hypoxia may play a role, and this can also be replicated in vitro to
determine whether this is an important factor in DD pathology and fibroblast activity.
Evidence exists that hypoxia may be important in fibrosis and in DD, both from the
epidemiological link to Diabetes and reduced peripheral circulation but also through more
mechanistic studies.
These issues highlight the complexity of fibrosis and replicating a useful model of fibrotic
disease in vitro. Clearly, in vivo, the Dupuytren disease fibroblasts produce excess
collagen I and this is sustained. However, this could not be replicated in the in vitro model
here using a culture of only fibroblasts and as outlined above this may be due to many
different factors that could be important. The use of more complex co-culture models (to
mimic the effects of inflammatory or epithelial cells), as well as physical constraints using
gels to mimic stiffness or stretch effects on the cells are likely to be important to more
closely mimic the in vivo situation and provide a significant difference in collagen
production between disease and unaffected cells. The fact that this does not appear to be
the case in keloid disease cells, which produce excess collagen I in vitro with no additional
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stimulus, is a very interesting finding. It suggests that whilst closely related in the fibrotic
pathology, keloid and Dupuytren’s disease are very distinct in their molecular pathology,
and this is worthy of further investigation.
5.4.1 Summary
This study suggests that the scar-in-a-jar assay for collagen production is not suitable for
assessing phenotypic variability between DD and normal skin fibroblasts. Therefore, other
in-vitro assays are required for investigation of functional mutations that may contribute
to DD. The findings also suggest that fibroblast activity in DD may be aberrant in-vivo
due to other factors. These could be physical changes to the matrix or other signaling
molecules produced from other cell types. Further investigation into the effects of matrix
stiffness on DD cell activity may clarify whether DD cells are sensitive to matrix changes
or whether other signaling is important. In addition, more complex in-vitro models
involving the use of multiple cell types may be warranted to understand the potential role
of cell signaling in promoting the progressive fibrosis observed in DD.
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CHAPTER SIX
6.1 Summary
To place this study in context I will quote from an early investigation by Terek et al (1995)
from Boston which sought to demonstrate that the gene for the B chain of platelet-derived
growth factor is expressed in Dupuytren’s contracture. “The presence of platelet-derived
growth factor B and its receptor in patients who have Dupuytren (sic) contracture suggests
that platelet-derived growth factor B (PDGFB) acting through an autocrine and paracrine
loop may account for the proliferation, contracture and abnormal biochemistry of
fibroblasts in Dupuytren contracture. Future treatment strategies may be directed at
reversing or counteracting this abnormality in gene expression“(Terek et al,1995).
In overtwenty years since that published article a large volume of research into
Dupuytren’s disease has focused on trying to identify the molecular pathology
underpinning Dupuytren’s disease. Whilst the fibromatous changes that occur during
Dupuytren’s disease are well characterized in contrast, despite the many studies, a clear
understanding of the molecular basis of the disease remains elusive. In 1994 Boerwinkle
and Chan wrote “It is a developing paradigm in medical practice and research that both
genetic and environmental factors are key contributors to disease aetiology and
pathophysiology (Boerwinkle and Chan, 1994). Whilst it is undoubtedly the case that
environmental factors play a role in the development of the disease, there is also strong
evidence for a genetic basis for the disease. It is clear that a large proportion of individuals
with the Dupuytren’s phenotype demonstrate a familial trait which is most commonly
found to be inherited in an autosomal dominant fashion with variable expression and
incomplete penetrance, based upon epidemiological studies. The difference in
Dupuytren’s disease incidence observed between different ethnicities also highlights an
important role for genetics.
In this thesis a combination of different genetic approaches has been used to investigate
the molecular pathology of Dupuytren’s disease in Western Australia. The justification
for further genetic investigation is the continued need to identify candidate genes
underlying Dupuytren’s pathology. By using a previously untried combination of genetic
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studies (Whole Exome Sequencing Analysis for family samples from those with mild and
severe disease and a Genome Wide Association Study of a WA population) the aim was
to use the combined datasets to identify genes that play functional roles in the development
of Dupuytren’s disease.
The genetic defects underlying inherited traits have traditionally been investigated
using linkage analysis which involved the use of microsatellite markers located
throughout the genome as the basis for identifying regions inherited only in affected
individuals within a family, ‘linking’ the causative defect to the regions identified. In
the case of Dupuytren’s disease, a previous linkage study performed in a Swedish
population was indicative of an important region being located on Chromosome 16.
(Hu et al., 2005). However, traditional linkage studies such as this have been limited
by low resolution and an inability to progress to identification of specific genes of
interest.
More recent approaches using single nucleotide polymorphisms (SNPs) as markers
throughout the genome to identify regions of interest have provided much higher
resolution and greater ability to identify gene mutations involved in disease (Stranger,
Stahl, & Raj, 2011). However, significant challenges in identifying causative
mutations and functional data still remained (Edwards, Beesley, French, & Dunning,
2013).

Functional mutations can be identified in specific genes by using whole exome
sequencing (WES) in studies of inherited diseases. This approach involves
sequencing the part of the genome encoding for proteins to identify non-synonymous
mutations that are likely to affect protein function and therefore underlie disease. It
has the significant advantage over GWAS methodology in actually identifying
functional mutations in specific genes that can be further characterized (Bao et al.,
2014; Rabbani et al., 2014)
The DNA of four related individuals with a clinical diagnosis of Dupuytren’s disease was
submitted for Whole Exome Sequencing (WES). Results obtained from sequencing these
four family members with Dupuytren’s phenotype provided a set of potentially important
mutations. However, no mutations of interest appeared to segregate with members of the

Investigating the Molecular Pathology of Dupuytren’s Disease

family that also had Dupuytren’s disease. No genes identified were similar to previous
studies using a GWAS approach or linkage approach (Hu et al, 2005; Holman et al, 2011).
Similarly, there was no overlap between the candidate genes identified and genes close to
SNPs that were potentially associated with Dupuytren’s disease in the Busselton study
(Chapter 3). Finally, related individuals with a severe disease phenotype were also
investigated using WES. It was hypothesized that these individuals may have different
mutations within the same genes as those with a mild phenotype that led to the more
aggressive disease. However no overlap between the genes identified in this study and the
previous studies was observed. Pathway analysis to identify potentially common pathways
affected by genes across the studies did not clearly identify important pathways that were
likely to be common across the individuals investigated. However, groups of genes with
related functions within each study suggests the pathology may not be directly related to
fibroblast activity but rather indirect influence on activity through other body systems.
6.2 Identification of causative mutations in Dupuytren’s disease
The current study has provided an analysis of DNA from three separate cohorts. The
limitations of these methods have been discussed in individual chapters and are dominated
by the inability to obtain sufficient statistical power for the GWAS study, limited numbers
within each family study and the complexity of incomplete penetrance of the disease.
Further whole exome sequencing of DNA obtained from two unrelated affecteds with a
clinical history and phenotype suggesting severe or aggressive disease identified a set of
different mutations, none of which demonstrated overlap with results of previous analyses.
They did bring to light two groups of genes, however, that might suggest alternative
pathways that could be significant in triggering this histology.
There are a number of key reasons that may contribute to the lack of commonality across
the genetic studies and to the continued difficulty in identifying key mutations in this
study. These include;
1. For the family and related individual WES studies the incomplete penetrance of
Dupuytren’s disease may impact on the findings. Whilst only family members that were
clinically assessed as positive cases of Dupuytren’s disease were initially sequenced to
identify potential causative mutations, confirmation required sequencing of identified
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mutations in both positive and negative DD family members to demonstrate segregation
of the mutation with the disease. However, it is possible that either due to age of some
individuals sequenced that they were yet to express the Dupuytren phenotype and were
incorrectly assigned as negative for DD. In addition, there may be members of the family
that were negative for DD but did inherit a contributing mutation and did not develop the
disease due to other environmental/genetic factors. There is also the possibility, since
Dupuytren’s disease is a common disease, that an individual family member with the
disease may have a sporadic cause rather than the same genetic mutation prevalent in the
family. There are also limitations of WES in the coverage and calling of each exon for
every gene. This can result in specific genes with lower coverage for individual exons and
lead to false negatives whereby mutations are not identified.
One key issue with using WES approach is that it will only identify mutations within the
coding region of genes. This is a small fraction of the genome and recent studies of the
human genome have clearly demonstrated the importance of entire regions of DNA that
are non-coding and that influence expression of genes. Therefore, it is possible that the
mutations do not lie within the exome at all and will be missed by this approach.

2. For the Busselton study which involved a GWAS type approach to a small population in
Western Australia the key limitation is the lack of power of the approach given the small
population and very small number of positive cases of Dupuytren’s disease. In addition,
those identified as positive for Dupuytren’s disease were not assessed by plastic surgeons
but were self-identified through questionnaires. Whilst this is unlikely to affect those that
reported having an operation for DD, those that report having banding within the palm
may be subject to misidentification. Another possible issue is the relatedness of the people
within the study. This can lead to the identification of SNPS not associated with the
disease but rather because a number of the affected individuals are more closely related
than the control population. Finally, given the wide range in age, it is possible that many
of the ‘unaffected’ in the Busselton study were not at the age where Dupuytren’s disease
would be apparent. This would result in the control samples containing a number of those
that are likely to develop DD in the future. However, this has a much smaller effect on the
study than the likely relatedness of the positive individuals.
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Two distinct approaches have largely been used to investigate DD. These are genetic
approaches, as described here and including GWAS studies, or alternatively a
transcriptome/proteomic approach interrogating disease-state cells for key changes when
compared to control cells. These proteomic/transcriptomic studies have focused on
isolating and investigating fibroblast activity as these are known to be the cells that drive
collagen production in fibrosis, a hallmark of DD and other fibrotic diseases. However,
the two key advantages of the genetic approach are that this does not assume a specific
cell type is the driver of disease, and this may be important given our increasing
understanding that fibrosis may be initiated and sustained by immune and other responses
which drive fibroblast collagen production rather than by aberrant fibroblast activity itself.
In addition, the advantage of the genetic approach is that the use of disease cells can inhibit
the ability to find changes that drive disease when there are multiple other changes that
are caused by the disease progression or are simply bystander changes associated with the
pathology. Again the genetic approach avoids the difficulty of sorting disease-associated
changes from disease-driving changes.

At this point in this study functional mutations have not been linked to the pathology of
Dupuytren’s disease. This may be due to limitations in the study or alternatively indicate
that rather than functional changes there are regulatory elements that drive DD pathology.
These include specific elements controlling gene expression and epigenetic changes. The
possible impact of these changes and methodology to investigate their involvement in DD
is discussed below.

6.3 Identification of functional elements beyond the parameters of Whole Exome
Sequencing – the ENCODE database.
There are many well defined elements within the human genome that influence the
expression of genes within the exome, and these have been investigated over many years,
with the discovery of Locus Control Regions (LCRs) and enhancer elements in DNA long
before the human genome sequence was completed. These types of regulatory elements
will not be identified using the WES approach described in this thesis. Since 2003 it has
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been possible to identify and characterize these functional elements in much more detail
in the human genome sequence and this work has been undertaken as part of a consortium
pursuing the ENCODE project (ENCyclopedia Of Dna Elements), which reported
preliminary results in 2007 and updated work in 2014 (Birney et al, 2007; Kellis et al,
2014). The findings of the ENCODE project demonstrate large numbers of conserved and
non-conserved elements through evolution that have significant impact on gene
expression. In addition, recent studies have increasingly focused on the roles of long noncoding RNA elements in regulating gene expression. This increasing awareness and
knowledge of the diversity of regulation of gene expression adds significantly to the
complexity of interrogating disease-causing mutations, particularly in diseases such as DD
where there are likely to be many factors that contribute to the disease. As with our
understanding of epigenetic regulation, this area is developing very rapidly and may lead
to novel insights into DD and other diseases as the information becomes better understood
and interpreted.

6.5 Epigenetic influences in control of gene expression.
In relation to fibroblast activity and collagen production there are many stages that
contribute to the regulation of collagen levels in the extracellular matrix, from posttranscriptional processing through to secretion, cross-linking and stability as well as
degradation. The control of gene expression is also a critical mechanism for normal cell
function. Epigenetic changes, that is changes to the DNA that are not sequence changes
but structural (commonly methylation status changes or histone changes in DNA
packaging) have been shown to be involved in several complex diseases including cancer
and in normal development and have been investigated in fibrotic and neural disorders.
Epigenetic changes result in increased and decreased expression of genes and are now
well described as being important in disease. From epigenetic studies several genes,
including Rasal1 in renal fibrosis (Bechtel et al, 2010; RASAL1 encoding an inhibitor of
the Ras oncoprotein), Fli1 in scleroderma (Wang et al, 2006) and Thy1 in pulmonary
fibrosis (Saunders et al, 2008) have been demonstrated to be hypermethylated and to
induce fibroblast proliferation and the production of collagen in fibrotic disease.
Therefore, it is feasible that there are epigenetic changes in DD that are important in the
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disease progression. However, to date no studies have clearly demonstrated a role for
epigenetic changes in the molecular pathology of DD. It is also possible that the epigenetic
changes described in fibrotic conditions arise as a result of cellular changes rather than
drive cellular change. Therefore, it will be important to characterize and understand
whether epigenetic changes and regulation play a role in DD.

6.6 Whole Genome Sequencing (WGS)
Kellis et al, (2014) have reviewed the strengths and limitations of biochemical,
evolutionary and genetic approaches for defining functional DNA segments and have
concluded that the elucidation of genome function will require a combination of all three
approaches (Kellis et al, 2014). The extensive GWAS study by Dolmans et al (2011),
published in the New England Journal of Medicine, implicated the Wnt signalling
pathway in the process of fibromatosis (as did Ojwang et al, 2010, and Shih et al, 2012),
but with the limitation of identifying a region of the genome but not the actual mutations
involved or the molecular changes involved in the disease progression. WGS does provide
an opportunity to interrogate the entire genome and any sequence changes that may
contribute to disease. However, because of the increasingly large sets of data that require
increasing numbers of patients to be interrogated, and often a lack of knowledge of the
function of many non-coding elements in the DNA, it will not necessarily provide an
opportunity to identify DD related mutations and their effects. This is in addition to the
possibility that epigenetic factors play a role and the influence of environmental factors
that may diminish the contribution of genetics to the disease phenotype. To date no WGS
approach to DD has been attempted. This may change as decreasing costs and increasing
speed of the approach, as well as better data analysis tools will make it more feasible for
the investigation of the genetics of disease.

6.7 The identification of molecular changes in DD using disease derived cells.
As mentioned above, the alternative approach to genetics that has been used to try to
identify important molecular changes in DD is cell isolation from diseased tissue and
either transcriptomic or proteomic profiling of these cells. A comparison of gene
expression in Dupuytren’s tissue against normal tissue has been reported by Forrester et
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al (2014), also by Zhang et al (2008) and others (reviewed in Bayat, 2012). The latter
demonstrated a dominant increase in TGF2 expression in Dupuytren’s cord tissue and
suggested that this gene expression profile could prove useful in developing a specific
gene therapy for this pathology. Shih et al (2009) also used a comparative analysis of
Dupuytren’s fibroblasts with tissue biopsies in disease-specific phenotypes for the
purpose of identifying biomarkers (Shih et al, 2009).
The study by Forrester et al (2014) analysed RNA isolated from five affected individuals,
but identified over three hundred genes that were either up-regulated or down-regulated
in the cultured Dupuytren’s fibroblasts. Their findings provide compelling evidence that
the development and progression of Dupuytren’s disease is closely associated with
significant up-regulation of a broad group of collagen genes and down-regulation of
matrix metallo-proteinase and collagenase genes involved in extracellular matrix
remodelling. These results are used to justify injection of Dupuytren’s with collagenase
from Clostridium histolyticum, a non-surgical treatment that has resulted in short-term
release of contractures in some cases while complicated by debilitating pain and
significant deep tissue adhesions in the longer term (Rozen et al, 2012).
Possibly the most significant genes up-regulated in the Dupuytren’s cells were two
Fibroblast Growth Factor genes KGF9 and FGF11, a suite of keratin genes (KRT34), and
others which are also involved in inflammatory diseases (Tumour Necrosis Factor) and
found in synovial fluid in osteoarthritis and rheumatoid arthritis (TNFAIP6 and VCAM1).
A number of genes identified as up-regulated were expressed in Diabetes and other
conditions sometimes associated with Dupuytren’s and are therefore not reliable
biomarkers of this condition.
As with other studies of this type the major limitation in the use of diseased cells is the
inability to separate driver and bystander changes in expression. In addition, these studies
have focused largely on fibroblasts, which whilst they clearly are responsible for the
increased collagen deposition observed, may not in themselves be pathogenic but rather
responding to signals from other cell types that actually trigger and stimulate disease.
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6.8 Possible non-fibroblast origin of Dupuytren’s disease
Several aspects of the familial inheritance and clinical and histological features of
Dupuytren’s disease within a specific family strongly support an autosomal genetic
component to the disease. Findings in other genetic based studies have often focused on
genes involved in the regulation of fibroblast activity, including pathological collagen
production and lattice contraction in the extra-cellular matrix, as well as apoptosis and
proliferation and alpha-smooth muscle actin expression. Even with whole genome and
linkage approaches the absence of definitive functional changes has led to the implicated
genes often being highlighted as likely to have important functions in fibroblasts. In
addition, those studies that have used Dupuytren tissue for transcriptome and proteomic
approaches, in addition to many of the histology and immunochemical studies have
focused on the fibroblast cells. This is understandable given the clear role of these cells in
the pathology of the disease. However, whilst fibroblasts clearly play a role in the disease
it is important to also focus on possible triggers and causes of the disease. This is feasible
with genetic approaches that do not involve cell isolation or proteomic profiling and can
lead to insight into processes that may underpin the changes that lead to Dupuytren
fibrosis.
The suggestion of a complex polygenic inheritance involving several pathways is readily
accepted in light of the variable expressivity and degree of phenotypic progression (Hu et
al, 2005; Gudmundsson et al, 2001). Differences may well depend upon the nature and
timing of trigger factors, some of which remain to be identified. The effect of direct trauma
to the hands remains uncertain, while some series depict Dupuytren’s as an occupational
hazard and others suggest that occupation involving repeated pressure on the palms may
have a contributory role in its aetiology. The occurrence of Dupuytren’s disease in females
and others with no history of manual labour would argue against the significance of
occupational trauma, while the very unequal incidence of Dupuytren’s between males and
females (6:1) invokes a possible hormonal influence and in particular fluctuations in
relation to ageing and menopause.
A review of external factors and the possible significance of their role in this disease has
reinforced the importance of certain ethnic, cultural and lifestyle factors, including
northern European origins, on the incidence of Dupuytren’s. Certain habits and co109

morbidities such as smoking and diabetes, which have been associated with Dupuytren’s
in many epidemiological surveys may well provide a trigger or facilitating role in
genetically susceptible individuals. In this regard it would seem that a parallel may exist
between Dupuytren’s fibromatosis and other diseases whose histochemical processes are
initiated and controlled by neuronal activity.

6.9 Neuronal activity/disruption and Dupuytren’s disease
The possibility of neuronal involvement in Dupuytren’s disease may be implicated from
the study findings. Rare mutations found in severe cases (Chapter 4) (eg BHMT,
CACNA1A, PRX); and in the family study (LRSAM1 )from Chapter 2 (Tandan et al, 1990)
are known to play important role in peripheral innervation. In particular, LRSAM1
identified as a candidate for Dupuytren’s (Ch2) is involved in a peripheral neuropathy and
this may be a significant factor if it has a role in DD.
Referring to the skin as a neuroimmunoendocrine organ Roosterman et al (2006) drew
attention to the neuronal function of the skin in numerous clinical disorders including
wound healing. The histochemical changes involving inflammation, cellular proliferation,
fibroblast activity and remodelling, which are characteristic of normal wound healing, also
occur in palmar fibromatosis. Neuropeptides released from the cutaneous innervation are
essential to neuroendocrine and neurovascular activity responsible for the cell
proliferation (abnormal myofibroblasts), cytokine and growth factor production, and
neovascularisation observed in progressive Dupuytren’s disease.
The involvement of neuronal pathways in the triggering or progression of palmar
fibromatosis is worth investigating further. Normal diagnostic histology has not identified
abnormal

nerve

patterns

in

Dupuytren’s

tissue

but

special

stains

and

immunohistochemistry could be applied to fresh sections or to cultured fibroblasts to
further investigate neuropeptides and growth factors produced by these cells. Specific
cellular activity may be observed by electron microscopy and the functional response of
myofibroblasts to a range of external stimuli may be tested in-vitro or in an animal model.
Further investigation of the role of sensory neurons and their secretomes in triggering
fibrosis has been suggested because of the frequent expression of cells capable of
producing neuropeptides commonly identified in all forms of fibrotic disease. There may
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be a genetic susceptibility to all of these conditions through mutations caused by infective,
immune, traumatic, neuroendocrine, metabolic or other physiological challenges, but the
subsequent pathway to progressive fibromatosis could involve a limited number of stages
which respond to variable functional mutations.
Secretomes such as cytokines and growth factors provide a favourable environment for
cell growth and proliferation, and much depends upon a balance between neurotrophins
and apoptosis. Subsequent remodelling depends on the relative activity of cell changes
and chemical structure of the extracellular matrix. The stages of proliferation and
remodelling are impacted by both genetic and environmental factors which accounts for
some of the variability in presenting phenotype.
A neuronal hypothesis could be tested by demonstration of in-vitro response of cultured
fibroblasts to neuropeptides and other secretomes, and possibly reinforced by positive
evidence of cell differentiation and proliferation. This work could be carried out using in
vitro models that mimic stretch and/or matrix stiffness to more closely mimic the
conditions of DD and provide insight into the interaction between innervation and fibrosis
in DD.
There is increasing evidence that the peripheral nervous system and autonomic nerves
may play an important role in mediating normal wound healing, a histochemical process
involving inflammation, cellular proliferation, fibroblast activity and remodelling
(Roosterman et al, 2006). These changes are also characteristic of the progressive
fibromatosis of Dupuytren’s disease and their common molecular basis may be
significant.
The processes involved in wound healing involve a combination of neuro-endocrine and
neurovascular activity, vital changes which are dependent upon neuropeptides released
from the cutaneous innervation. These changes are also characteristic of the progressive
fibromatosis of Dupuytren’s disease. The fundamental processes of healing and scar
formation include cell migration and proliferation, inflammation, synthesis and secretion
of cytokines and extracellular matrix proteins and remodeling. In individuals with a
familial predisposition, some of these changes can become excessive in formation of
keloid and hypertrophic scars. In keloids keratinocytes induce fibroblasts to secrete
Connective Tissue Growth Factor (CTGF), a downstream mediator of the role of
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Transforming Growth Factor  (TGF) in enhancing fibrosis. Keratinocytes also directly
increase the proliferation of underlying dermal fibroblasts while decreasing their
production of collagen.
In summary, innervation plays an important role in wound repair and tissue maintenance
and has been demonstrated to be critical to repair in the skin. It is possible that innervation
also plays a role in the pathobiology of DD and this warrants further investigation.

6.10 Angiogenesis and a role for vascular changes in Dupuytren’s disease
The pathological remodelling of connective tissue characteristic of scleroderma is
suggestive of fundamental interactions between microvascular damage and inflammation
linked to tissue fibrosis (Abraham and Varga, 2005). This complex autoimmune disease
results in abnormally fibrotic scars in areas of increased tension (cf hypertrophic scars)
with induction of Connective Tissue Growth Factor (CTGF) by Transforming Growth
Factor  (TGF), a process that may be suppressed by Tumour Necrosis Factor alpha. The
anti-sclerotic effect of TGF antibody was demonstrated in a mouse model with
bleomycin-induced scleroderma (Yamamoto et al, 2005). Angiogiotensin II (ANG II)
appears to inﬂuence tissue repair via activation of angiotensin I receptor (AT1R) in
ﬁbroblasts, leading to collagen remodelling, collagen gel contraction, and upregulation of
collagen-binding integrins in-vitro (Watson et al, 1998). Platelet-derived growth factor
(PDGF) also plays an essential role in embryo development and is critical for tissue repair.
Overactivity of PDGF has been linked to tumour progression of glioblastoma and
sarcomas and has also been implicated in atherosclerosis and several fibrotic conditions,
including pulmonary fibrosis, renal fibrosis, hepatic cirrhosis, and myelofibrosis (Heldin
et al, 1999, 2013; Bonner, 2004). PDGFR alpha also facilitates infections by certain
viruses (Soroceanu et al, 2008).
In Dupuytren’s contracture both PDGF A- and B-chain were expressed by primary cell
cultures from palmar fibromatosis, and the expression increased when the cells were
subjected to mechanical strain (Alman et al, 1995,1996). An immunohistochemical
analysis revealed that PDGF A- and B-chains are present in infiltrating inflammatory
cells. The synthesis of PDGF by inflammatory cells is often increased in response to
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external stimuli such as exposure to low oxygen tension or stimulation by other growth
factors and cytokines. PDGF receptors are upregulated, suggesting a role for PDGF in
mesenchymal cell proliferation in some autoimmune diseases including rheumatoid
arthritis and scleroderma, both conditions not normally associated with Dupuytren’s
disease. The possibility that reduced innervation and hypoxia contribute to DD is also
suggested by the association of Diabetes and concurrent reduction in peripheral circulation
with the development of DD. In the studies reported here genes with roles in angiogenesis
and vascularization were identified as being candidates of interest with functional
mutations. These may be investigated further as this work is progressed to continue to try
to identify functional changes involved in DD.

6.11 Fibroblasts, ECM changes and Dupuytren’s disease
Dermal fibroblasts (DF) represent the main cellular component of the dermis and are
implicated in the homeostatic maintenance of skin extracellular matrix (ECM). They are
metabolically active cells and their role is associated with the synthesis and secretion of
collagens, proteoglycans, ﬁbronectin, and metalloproteases. Dermal ﬁbroblasts are
involved in physio-pathological processes, including wound healing and ﬁbrosis (Krieg et
al., 2007; Werner et al., 2007) and have therefore been the dominant focus of research into
fibrotic diseases, including DD. After injury, different factors, in particular TGF
(Desmouliere et al., 2003), promote dermal fibroblast differentiation into myoﬁbroblasts
(DM), characterized by the expression of alpha Smooth Muscle Actin (-SMA) (Hinz,
2007), which is therefore used as a myofibroblast differentiation marker. The dermal
myofibroblasts are the key effector in injury/repair processes and ﬁbrosis, as they control
ECM component deposition, tissue contraction and wound resolution (Hinz, 2007), and
their subsequent apoptosis is essential for tissue re-epithelization (Desmouliere et al.,
2005). Whilst fibroblasts are clearly a key cell type involved in the pathology of DD, in
this study candidate one key advantage of the genetic approaches used in this study (and
others) is that unlike tissue based DD studies that have isolated fibroblasts from disease
tissue to characterize the changes involved the genetic studies allow the identification of
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genes that may be important but not related to fibroblast activity. This has clearly been
seen in this study as not only matrix genes but other pathways have been highlighted.
Interestingly one possible hypothesis that has not been extensively explored to explain
DD pathology is the threshold effect that is seen in mitochondrial disorders (Bayat et al,
2004). Severe cases of fibromatosis affecting both hands and feet tend to be particularly
common in individuals with a positive family history. Interestingly, a known familial
condition affecting the palms and the soles (palmoplantar keratoderma) associated with
sensorineural hearing loss is attributable to a specific mitochondrial mutation A7445G
(Sevior et al, 1998). Mitochondrial DNAs with substantial mutations replicate more
rapidly than normal mitochondrial DNAs, a disproportion more noticeable in some
specific tissues (eg muscle) and considered to be related to increasing age (Weber et al,
1997). The variation in age of onset of Dupuytren’s fibromatosis may be related to the
rate of accumulation and percentage of accumulated mutated mitochondrial DNA in
affected tissues. This may be an alternative explanation for changes in fibroblast activity
unrelated to changes in the cellular DNA or gene expression but linked instead to the
mitochondria.

6.12 Infection and Immune system involvement in DD

A number of degenerative neurological disorders are also known to be caused by viruses,
and it is this intimate association with gene mutations with functional diversity that
provides a possible driver for the immunogenetic pathway of Dupuytren’s pathology (Li
Zhou, 2013).
The presence of inflammatory cells, including multinucleated macrophages in healing
wounds, scar tissue and the fibromatoses including Dupuytren’s disease, is considered an
indication of immune response to either tissue antigens or foreign proteins including
viruses. The significance of immunological pathways in any phase of disease where
inflammation is apparent in response to viral infection or other stimulus is that they may
represent a broader target in terms of prevention or treatment (Deleidi and Isacson, 2012).
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Verjee et al (2013), in a study of freshly isolated tissue from Dupuytren’s patients, found
that it contained significant numbers of immune cells including activated macrophages
and released proinflammatory protein mediators (cytokines). Of the latter only TNF
selectively converted normal fibroblasts from the palm of patients with Dupuytren’s
disease into myofibroblasts via activation of the Wnt signaling pathway.
In 1990 Bower and co-workers published data on Dupuytren’s disease in a cohort of men
with complications of severe HIV infection. Rather surprisingly this group of men with
an age range of 19 to 54 years showed a prevalence of 36% with Dupuytren’s disease
(compared with an expected 4-6% in the general population, even less in this younger age
group). The purpose of their study was to investigate further the role of free radicals, as
proposed by Murrell et al in 1987, in the pathogenesis of Dupuytren’s disease. Superoxide
free radicals produced as a result of ischaemia-related conversion of xanthine
dehydrogenase to xanthine oxidase are thought to induce proliferation of fibroblasts and
the production of type III collagen (Murrell et al, 1987).
The rather high prevalence of Dupuytren’s among patients with HIV (Human
Immunodeficiency Virus) infection was thus linked with disturbed metabolism of free
radicals. Although HIV may have originated as early as 1920, the pivotal year appears to
be 1981 when previously healthy young gay men in Los Angeles developed a rare lung
infection called Pneumocystis carinii pneumonia (PCP), and by December of that year
there were 270 reported cases of severe immune deficiency among gay men and injected
drug users with 121 fatalities. There were also reports of men in New York and California
with unusually aggressive Kaposi’s Sarcoma.
Although there are an estimated 35 million individuals worldwide now living with AIDS,
the majority of them in sub-Saharan Africa, no further reference to an association with
Dupuytren’s disease is available. But the potentially fatal Kaposi’s sarcoma, an
aggressively malignant lymphovascular fibromatosis which is caused by Human Herpes
Virus VIII, is most commonly found now in men with AIDS.
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6.13 Future studies
The current study has included identification of thirty-one candidate genes from whole
exome sequencing of DNA in four related family affecteds (Chapter 2; Table 2.4). These
mutations were selectively screened against SNP databases and further restricted to twelve
non- synonymous heterozygous mutations, of which two were in regions of positive
linkage. Sanger sequencing of PCR fragments was focused on 3 candidate genes to
determine whether these mutations segregated within the family in members with
Dupuytren’s disease. GORASP1 and EXOG genes were both selected due to their
identification in a region of positive linkage from initial analysis. In addition, COL6A5
was also selected for sequencing due to the fundamental link between collagen deposition
and fibrotic disease. Initial sequencing showed that no mutation segregated with the
disease in additional family members. Further investigation of the other non-synonymous
mutations identified in four (affected) family members (Table 2.5) could possibly identify
significant segregation with Dupuytren’s.

Whole exome sequencing from a limited number of family affecteds has possibly
restricted the number of identifiable potential candidate genes for further investigation.
Ideally the cohort could be expanded to include Dupuytren’s phenotype in other
generations, as well as non-affecteds, which might provide evidence to reinforce the
current findings.
The problem remains with the large number of possible candidates that have been
excluded by the selection process, all of them identified in DNA from family members
with Dupuytren’s and a number that were found to occur in all family members.
As expected, the WES has identified only those genes with a functional role, sequencing
the part of the genome encoding for proteins to identify non-synonymous mutations that
are likely to affect protein function rather than those affecting expression levels. Further
sequencing of additional variants found in all family members to identify mutations that
segregate with Dupuytren’s disease would be useful. Whole Genome sequencing has been
mentioned previously as a possible approach while acknowledging the financial
limitations and an anticipated burden of genetic information.
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A further study of severe cases would be justified and more significant results could be
obtained from an expanded cohort with aggressive Dupuytren’s disease, including related
individuals with this condition. While different genes may be involved in severe cases
their variance might be related to environmental or epigenetic factors and some gene
overlap with those currently identified could still occur.
Comparison with other fibrotic diseases at a molecular level has already provided some
understanding of the processes involved and it is reasonable to maintain a belief in the
common pathways hypothesis while understanding that not only the characteristic tissue
structures but also trigger mechanisms will account for phenotypic variations.
The eventual challenge of fibroblast activity and function in relation to chemical and
neuronal responses will rest with laboratory tests in vitro, including epigenetic regulation
of gene expression in relation to fibroblast activity.
Our ultimate goal must be to determine the molecular mechanisms that control the
pathogenesis of Dupuytren’s disease with the aim of prevention and/or treatment by
molecular control.

For the functional annotation of genetic elements in a familial

condition such as Dupuytren’s CRISPR would be ideal for identifying and targeting
specific genetic mutations eg those candidate genes identified by exome sequencing
(Chapters 2/4) and/or mutations identified in previous studies and presumed to be involved
in the pathogenesis of Dupuytren’s disease. It would be useful to correct or modifiy these
genes and observe changes in the cell phenotype and function in-vitro. This would provide
strong evidence for a causative link between the mutations and the clinical disease state.
The application of CRISPR in genome-wide studies would also enable large-scale
screening for therapeutic targets and other phenotypes and will facilitate the generation of
engineered animal models that would benefit pharmacological studies and the
understanding and treatment of the human condition.

6.14 Summary
Possibly for the first time an integrated approach has been taken to determine a genetic
basis for Dupuytren’s disease. The combination of a familial cohort subjected to Whole
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Exome Sequencing (WES), a larger cohort of affecteds from a community population
survey whose DNA was sequenced by Genome Wide Association (GWAS), and a very
limited number of unrelated individuals with evidence of a severe phenotype (WES), has
not previously been reported. Although a number of candidate genes were identified as
non-synonymous for Dupuytren’s in each cohort there was no overlap between these three
groups. The hypothesis has not been proven. However, further studies of those mutations
involving the application of specific biomarkers to Dupuytren’s fibroblasts in-vitro could
determine specific cellular response and validate the ability of certain genes to regulate
apoptosis, proliferation, myofibroblast differentiation, collagen and alpha smooth muscle
actin expression and fibroblast-populated collagen lattice contraction.
Comparisons with results from other similar studies including Dupuytren’s tissue DNA
sequencing have also failed to identify positive overlap. The author agrees with previous
researchers in concluding that the underlying cause of Dupuytren’s fibromatosis is a
complex system of polygenic pathways facilitated or triggered by a variety of
environmental factors. It remains possible, however, that further studies of neuronal
pathways and their influence on aetiology and pathogenesis of fibromatosis could displace
current theory regarding cell differentiation and proliferation in Dupuytren’s disease.
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